{
  "id": "topic5",
  "title": "Topic 5: Inborn Errors of Metabolism - Comprehensive Board Study Guide",
  "description": "[â¬†ï¸ Back to Master Index](study-guide-master-index.",
  "difficulty": "Advanced",
  "tags": [
    "metabolic",
    "inborn-errors",
    "enzyme",
    "metabolism"
  ],
  "estimatedTime": 38,
  "importance": 1,
  "sections": [
    {
      "id": "quick-navigation",
      "title": "Quick Navigation",
      "content": "**[â¬†ï¸ Back to Master Index](study-guide-master-index.md)** | **[â¬…ï¸ Previous: Neurological Disorders](topic4-neurological-developmental.md)** | **[â¡ï¸ Next: Final Topic](topic6-final-topic.md)**\n\n### ğŸ“‹ Table of Contents\n- [ğŸ¯ Learning Objectives](#-learning-objectives)\n- [ğŸ“Š Overview of Metabolic Disorders](#-overview-of-metabolic-disorders)\n- [ğŸ§¬ Amino Acid Disorders](#-amino-acid-disorders)\n  - [Phenylketonuria (PKU) â­â­â­](#phenylketonuria-pku-)\n  - [Homocystinuria â­â­](#homocystinuria-)\n  - [Tyrosinemia Type I â­â­](#tyrosinemia-type-i-)\n- [ğŸ§ª Organic Acidemias](#-organic-acidemias)\n  - [Methylmalonic Acidemia (MMA) â­â­â­](#methylmalonic-acidemia-mma-)\n  - [Propionic Acidemia â­â­](#propionic-acidemia-)\n  - [Maple Syrup Urine Disease (MSUD) â­â­](#maple-syrup-urine-disease-msud-)\n- [ğŸ¬ Carbohydrate Disorders](#-carbohydrate-disorders)\n  - [Galactosemia (Classic) â­â­â­](#galactosemia-classic-)\n  - [Glycogen Storage Disease Type I â­â­](#glycogen-storage-disease-type-i-von-gierke-)\n  - [Glycogen Storage Disease Type II â­â­](#glycogen-storage-disease-type-ii-pompe-)\n- [ğŸ§¬ Lysosomal Storage Disorders](#-lysosomal-storage-disorders)\n  - [Gaucher Disease â­â­â­](#gaucher-disease-)\n  - [Tay-Sachs Disease â­â­â­](#tay-sachs-disease-)\n  - [Fabry Disease â­â­â­](#fabry-disease-)\n- [ğŸ§¬ Mucopolysaccharidoses (MPS)](#-mucopolysaccharidoses-mps)\n- [ğŸ§¬ Peroxisomal & Fatty Acid Oxidation Disorders](#-peroxisomal--fatty-acid-oxidation-disorders)\n- [ğŸ§¬ Metal Transport Disorders](#-metal-transport-disorders)\n- [ğŸ§¬ Other Key Metabolic Disorders](#-other-key-metabolic-disorders)\n- [ğŸ“‹ Study Aids & Mnemonics](#-study-aids--mnemonics)\n- [ğŸ¯ High-Yield Board Facts](#-high-yield-board-facts)\n- [ğŸ“ Practice Questions](#-practice-questions)\n- [âœ… Topic 5 Completion Checklist](#-topic-5-completion-checklist)\n\n### ğŸ” Quick Disorder Lookup\n| Disorder | Gene/Defect | Key Features | Inheritance | NBS |\n|----------|-------------|--------------|-------------|-----|\n| **PKU** | PAH | ID without treatment, musty odor | AR | Yes |\n| **Galactosemia** | GALT | Liver disease, E. coli sepsis | AR | Yes |\n| **MCAD** | ACADM | Hypoketotic hypoglycemia | AR | Yes |\n| **Gaucher** | GBA | Hepatosplenomegaly, bone disease | AR | No |\n| **Tay-Sachs** | HEXA | Cherry-red spot, neurodegeneration | AR | No |\n| **Fabry** | GLA | Acroparesthesias, angiokeratomas | X-linked | Some |\n| **Hunter (MPS II)** | IDS | NO corneal clouding | X-linked | No |\n| **Wilson** | ATP7B | K-F rings, liver disease | AR | No |\n| **FH** | LDLR | Very high LDL, xanthomas | AD | No |\n\n### ğŸ† Board Exam Domain Coverage\n- **Primary Domain:** Clinical Genetics (40-50%)\n- **Secondary Domains:** General Genetics/Genomics (15-25%)\n- **Difficulty Level:** Intermediate to Advanced\n- **Estimated Study Time:** 15-18 hours\n- **Last Updated:** July 2025\n\n---",
      "importance": 1
    },
    {
      "id": "learning-objectives",
      "title": "Learning Objectives",
      "content": "By the end of this topic, you should be able to:\n\n1. **Identify** which metabolic disorders are included in newborn screening panels and their follow-up protocols\n2. **Calculate** carrier risks for metabolic disorders in specific populations (Ashkenazi Jewish, Finnish, etc.)\n3. **Counsel** families on dietary management for PKU, galactosemia, and other treatable conditions\n4. **Distinguish** between different types of metabolic disorders based on clinical presentation and biochemical findings\n5. **Explain** enzyme replacement therapy options and their implications for genetic counseling\n6. **Apply** consanguinity risk calculations for autosomal recessive metabolic disorders\n7. **Recognize** metabolic emergencies and appropriate management protocols\n8. **Compare** population-based carrier screening programs (Tay-Sachs, Gaucher) and their effectiveness\n9. **Interpret** biochemical test results including amino acid profiles and enzyme activity levels\n10. **Describe** inheritance patterns and recurrence risks for all major metabolic disorders\n11. **Evaluate** treatment compliance challenges and psychosocial impacts on families\n12. **Demonstrate** understanding of metabolic pathways and their disruption in disease states\n\n---",
      "importance": 1
    },
    {
      "id": "overview-of-metabolic-disorders",
      "title": "Overview of Metabolic Disorders",
      "content": "<details>\n<summary><strong>ğŸ“Š Classification by Pathway</strong> (Click to expand)</summary>\n\n### Classification by Pathway\n1. **Small molecule diseases** - accumulation of toxic metabolites\n   - Amino acid disorders\n   - Organic acidemias\n   - Urea cycle defects\n2. **Large molecule diseases** - storage of complex molecules\n   - Lysosomal storage disorders\n   - Mucopolysaccharidoses\n   - Glycogen storage diseases\n3. **Energy metabolism defects**\n   - Fatty acid oxidation disorders\n   - Mitochondrial disorders\n\n### Key Counseling Concepts\n- **Newborn screening**: Early detection â†’ prevention of irreversible damage\n- **Dietary management**: Lifelong compliance challenges\n- **Carrier screening**: Population-specific risks\n- **Enzyme replacement**: Cost, access, effectiveness\n- **Prenatal diagnosis**: Options and timing\n- **Emergency protocols**: Metabolic crisis management\n\n</details>\n\n**[â¬†ï¸ Back to Top](#-quick-navigation)**\n\n---",
      "importance": 1
    },
    {
      "id": "amino-acid-disorders",
      "title": "AMINO ACID DISORDERS",
      "content": "### Phenylketonuria (PKU) â­â­â­\n**Most Common Amino Acid Disorder - High Board Yield\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Intellectual disability** if untreated\n2. **Musty body odor**\n3. **Fair skin/hair** (decreased pigmentation)\n\n<details>\n<summary><strong>ğŸ¥ Clinical Features</strong> (Click to expand)</summary>\n\n- **Neurological**: Progressive ID without treatment, seizures, behavioral problems\n- **Dermatologic**: Eczema, decreased melanin â†’ fair complexion\n- **Metabolic**: Elevated phenylalanine, low tyrosine\n- **Other**: Musty/mousy odor (phenylacetic acid in urine/sweat)\n\n</details>\n\n<details>\n<summary><strong>ğŸ§ª Biochemistry & Testing</strong> (Click to expand)</summary>\n\n- **Defect**: Phenylalanine hydroxylase (PAH) deficiency\n- **Pathway**: Phenylalanine â†’ Tyrosine (blocked)\n- **NBS**: Tandem MS - elevated phenylalanine\n- **Confirmation**: Plasma amino acids, PAH gene sequencing\n- **Classification**:\n  - Classic PKU: Phe >1200 Î¼mol/L\n  - Moderate PKU: Phe 600-1200 Î¼mol/L\n  - Mild PKU: Phe 360-600 Î¼mol/L\n  - Mild hyperphe: Phe 120-360 Î¼mol/L\n\n</details>\n\n<details>\n<summary><strong>ğŸ¥— Treatment & Management</strong> (Click to expand)</summary>\n\n- **Diet**: Low phenylalanine diet (avoid high protein foods)\n- **Formula**: Phe-free medical foods\n- **Monitoring**: Regular Phe levels\n- **New therapies**: \n  - Sapropterin (Kuvan) - BH4 cofactor supplementation\n  - Pegvaliase (Palynziq) - enzyme substitution therapy\n- **Goal Phe levels**: \n  - <12 years: 120-360 Î¼mol/L\n  - >12 years: 120-600 Î¼mol/L\n  - Pregnancy: 120-360 Î¼mol/L\n\n</details>\n\n<details>\n<summary><strong>ğŸ‘¶ Maternal PKU Syndrome</strong> (Click to expand)</summary>\n\n- **Risks if Phe >360 Î¼mol/L during pregnancy**:\n  - Microcephaly (73%)\n  - ID/DD (92%)\n  - Congenital heart disease (12%)\n  - IUGR (40%)\n- **Prevention**: Strict diet control BEFORE conception\n- **Monitoring**: Weekly Phe levels during pregnancy\n\n</details>\n\n<details>\n<summary><strong>ğŸ“ˆ Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Pattern**: Autosomal recessive\n- **Gene**: PAH (12q23.2)\n- **Prevalence**: 1:10,000-15,000 (US)\n- **Carrier frequency**: \n  - General: 1:50-60\n  - Turkish: 1:25\n  - Irish: 1:30\n\n</details>\n\n#### ğŸ’ Board Pearls\n- Cannot test Phe/Tyr ratio if on birth control or pregnant\n- Most common inborn error of amino acid metabolism\n- All 50 states include PKU in NBS\n- Offspring of PKU mothers: 100% carriers, at risk for maternal PKU effects\n- Compliance challenges increase in adolescence\n\n**[â¬†ï¸ Back to Top](#-quick-navigation)** | **[â¡ï¸ Next: Homocystinuria](#homocystinuria-)**\n\n---\n\n### Homocystinuria â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Ectopia lentis** (downward lens dislocation)\n2. **Marfanoid habitus**\n3. **Thromboembolism risk**\n\n<details>\n<summary><strong>ğŸ¥ Clinical Features</strong> (Click to expand)</summary>\n\n- **Ocular**: Ectopia lentis (85%), myopia, glaucoma\n- **Skeletal**: Tall stature, arachnodactyly, scoliosis, osteoporosis\n- **Vascular**: Thromboembolism (50% by age 30)\n- **Neurologic**: ID variable, seizures, psychiatric symptoms\n- **Other**: Fair complexion, malar flush\n\n</details>\n\n<details>\n<summary><strong>ğŸ§ª Biochemistry & Testing</strong> (Click to expand)</summary>\n\n- **Defect**: Cystathionine Î²-synthase (CBS) deficiency (most common)\n- **Pathway**: Homocysteine â†’ Cystathionine (blocked)\n- **NBS**: Not universally screened\n- **Testing**: \n  - Plasma homocysteine (elevated)\n  - Plasma methionine (elevated in CBS deficiency)\n  - Urine homocystine\n- **Other causes**: MTHFR deficiency, B12 metabolism defects\n\n</details>\n\n<details>\n<summary><strong>ğŸ¥— Treatment & Management</strong> (Click to expand)</summary>\n\n- **B6 responsive (50%)**: High-dose pyridoxine\n- **B6 non-responsive**: \n  - Low methionine diet\n  - Cystine supplementation\n  - Betaine (lowers homocysteine)\n- **Thrombosis prevention**: Aspirin, avoid surgery/dehydration\n- **Folate/B12**: For other forms\n\n</details>\n\n<details>\n<summary><strong>ğŸ“ˆ Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Pattern**: Autosomal recessive\n- **Gene**: CBS (21q22.3)\n- **Prevalence**: 1:200,000-335,000\n- **Note**: Heterozygotes may have mild â†‘ homocysteine â†’ cardiovascular risk\n\n</details>\n\n#### ğŸ’ Board Pearls\n- Lens dislocation: DOWN and OUT (vs Marfan: UP)\n- Major cause of preventable ID if B6 responsive\n- Screen before surgery due to thrombosis risk\n- Can be missed on NBS if mild or late-onset\n\n**[â¬†ï¸ Back to Top](#-quick-navigation)** | **[â¡ï¸ Next: Tyrosinemia Type I](#tyrosinemia-type-i-)**\n\n---\n\n### Tyrosinemia Type I â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Liver failure** in infancy\n2. **Renal tubular dysfunction**\n3. **\"Cabbage-like\" odor**\n\n<details>\n<summary><strong>ğŸ¥ Clinical Features</strong> (Click to expand)</summary>\n\n- **Hepatic**: Acute liver failure, cirrhosis, hepatocellular carcinoma\n- **Renal**: Fanconi syndrome, rickets\n- **Neurologic**: Painful crises (peripheral neuropathy)\n- **Other**: Failure to thrive, coagulopathy\n\n</details>\n\n<details>\n<summary><strong>ğŸ§ª Biochemistry & Testing</strong> (Click to expand)</summary>\n\n- **Defect**: Fumarylacetoacetate hydrolase (FAH) deficiency\n- **Pathway**: Tyrosine degradation pathway (final step blocked)\n- **NBS**: Succinylacetone (pathognomonic)\n- **Testing**: \n  - Urine organic acids: succinylacetone\n  - Plasma amino acids: â†‘ tyrosine\n  - AFP: markedly elevated\n\n</details>\n\n<details>\n<summary><strong>ğŸ¥— Treatment & Management</strong> (Click to expand)</summary>\n\n- **NTBC (nitisinone)**: Blocks upstream enzyme\n- **Diet**: Low tyrosine, low phenylalanine\n- **Monitoring**: AFP for HCC surveillance\n- **Liver transplant**: If medical management fails\n\n</details>\n\n<details>\n<summary><strong>ğŸ“ˆ Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Pattern**: Autosomal recessive\n- **Gene**: FAH (15q25.1)\n- **Prevalence**: 1:100,000\n- **High risk**: French Canadian (Saguenay) 1:1,850\n\n</details>\n\n#### ğŸ’ Board Pearls\n- Dramatically improved prognosis with NTBC\n- Succinylacetone is pathognomonic\n- High HCC risk even with treatment\n- Type II: eye/skin findings; Type III: mild ID\n\n**[â¬†ï¸ Back to Top](#-quick-navigation)** | **[â¡ï¸ Next: Organic Acidemias](#-organic-acidemias)**\n\n---",
      "importance": 1
    },
    {
      "id": "organic-acidemias",
      "title": "\uddea ORGANIC ACIDEMIAS",
      "content": "### Methylmalonic Acidemia (MMA) â­â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Metabolic acidosis** with anion gap\n2. **Hyperammonemia**\n3. **Elevated C3 on acylcarnitine profile**\n\n#### ğŸ¥ Clinical Features\n- **Acute presentation**: Lethargy, vomiting, dehydration\n- **Metabolic**: Ketoacidosis, hyperammonemia\n- **Neurologic**: Encephalopathy, developmental delays\n- **Hematologic**: Pancytopenia\n- **Renal**: Progressive CKD\n- **Long-term**: Basal ganglia strokes\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Methylmalonyl-CoA mutase OR cobalamin metabolism\n- **NBS**: â†‘ C3 (propionylcarnitine)\n- **Confirmation**: \n  - Urine organic acids: methylmalonic acid\n  - Plasma amino acids: â†‘ glycine\n  - B12 levels\n- **Subtypes**: \n  - mutâ°: No enzyme activity\n  - mutâ»: Reduced enzyme activity\n  - cbl A-G: Cobalamin metabolism defects\n\n#### ğŸ¥— Treatment & Management\n- **Acute**: IV glucose, bicarbonate, carnitine\n- **Chronic**: \n  - Protein restriction (1-1.5 g/kg/day)\n  - Medical formula\n  - L-carnitine supplementation\n  - B12 (responsive forms)\n- **Emergency protocol**: Written plan for illness\n- **Transplant**: Liver or combined liver-kidney\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Genes**: MUT, MMAA-MMAB, others\n- **Prevalence**: 1:50,000-120,000\n- **High risk populations**: Saudi (1:3,500)\n\n#### ğŸ’ Board Pearls\n- Some forms B12 responsive - always trial\n- Combined with homocystinuria = cbl C defect\n- Risk of metabolic stroke during crisis\n- Sibling recurrence: 25%\n\n---\n\n### Propionic Acidemia â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Metabolic acidosis** with ketosis\n2. **Hyperammonemia**\n3. **Cardiomyopathy** (late complication)\n\n#### ğŸ¥ Clinical Features\n- **Acute**: Similar to MMA - lethargy, vomiting\n- **Metabolic**: Ketoacidosis, hyperammonemia, hypoglycemia\n- **Neurologic**: Seizures, basal ganglia changes\n- **Cardiac**: Dilated cardiomyopathy, arrhythmias\n- **GI**: Pancreatitis\n- **Immunologic**: T-cell dysfunction\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Propionyl-CoA carboxylase\n- **NBS**: â†‘ C3\n- **Confirmation**: \n  - Urine organic acids: 3-hydroxypropionate, methylcitrate\n  - Enzyme assay in fibroblasts\n\n#### ğŸ¥— Treatment & Management\n- **Similar to MMA**: Protein restriction, medical formula\n- **Biotin**: Trial (rarely responsive)\n- **Avoid**: Propiogenic amino acids (Val, Ile, Met, Thr)\n- **Cardiac monitoring**: Echo, EKG\n- **Liver transplant**: Consideration\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Genes**: PCCA, PCCB\n- **Prevalence**: 1:100,000\n- **High risk**: Saudi Arabia, Amish\n\n---\n\n### Maple Syrup Urine Disease (MSUD) â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Sweet maple syrup odor** (urine, cerumen)\n2. **Encephalopathy** in newborn period\n3. **Elevated branched-chain amino acids**\n\n#### ğŸ¥ Clinical Features\n- **Classic form (85%)**: \n  - Normal at birth\n  - Poor feeding by 2-3 days\n  - Encephalopathy by 4-5 days\n  - Characteristic odor\n- **Neurologic**: Alternating hyper/hypotonia, seizures\n- **Metabolic**: Ketoacidosis, hypoglycemia\n- **Intermediate/intermittent**: Later onset, triggered by illness\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Branched-chain Î±-ketoacid dehydrogenase complex\n- **NBS**: â†‘ leucine, isoleucine, valine\n- **Confirmation**: \n  - Plasma amino acids: â†‘ BCAAs\n  - Urine organic acids: branched-chain ketoacids\n  - Alloisoleucine (pathognomonic)\n\n#### ğŸ¥— Treatment & Management\n- **Acute**: Hemodialysis may be needed\n- **Diet**: Restrict BCAAs (leucine most toxic)\n- **Medical formula**: BCAA-free\n- **Thiamine**: Trial (responsive forms exist)\n- **Monitoring**: Frequent amino acid levels\n- **Emergency**: IV glucose, avoid catabolism\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Genes**: BCKDHA, BCKDHB, DBT, DLD\n- **Prevalence**: 1:185,000\n- **High risk**: Old Order Mennonites (1:380)\n\n#### ğŸ’ Board Pearls\n- Can have normal intelligence if well-controlled\n- Leucine is most neurotoxic BCAA\n- Smell may be subtle - check earwax\n- Metabolic crisis with minor illness\n\n---\n\n### Isovaleric Acidemia â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **\"Sweaty feet\" odor**\n2. **Metabolic acidosis**\n3. **Elevated C5 on NBS**\n\n#### ğŸ¥ Clinical Features\n- **Acute neonatal**: Vomiting, lethargy, acidosis\n- **Chronic intermittent**: Episodes during illness\n- **Odor**: Characteristic \"sweaty feet\" smell\n- **Neurologic**: Variable developmental outcome\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Isovaleryl-CoA dehydrogenase\n- **NBS**: â†‘ C5 (isovalerylcarnitine)\n- **Confirmation**: \n  - Urine organic acids: isovalerylglycine\n  - Plasma acylcarnitines\n\n#### ğŸ¥— Treatment & Management\n- **Diet**: Leucine restriction (mild)\n- **Carnitine**: Enhances excretion\n- **Glycine**: Conjugation therapy\n- **Avoid**: Fasting, high protein\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: IVD\n- **Prevalence**: 1:250,000\n\n---\n\n### Alkaptonuria â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Black urine** (on standing/alkalinization)\n2. **Ochronosis** (dark pigmentation)\n3. **Arthritis** in adulthood\n\n#### ğŸ¥ Clinical Features\n- **Urine**: Darkens on standing or with alkali\n- **Ochronosis**: Blue-black cartilage pigmentation\n  - Ear cartilage\n  - Sclera\n  - Heart valves\n- **Arthritis**: Large joints, spine (30s-40s)\n- **Cardiac**: Valve disease, CAD\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Homogentisate 1,2-dioxygenase\n- **Testing**: \n  - Urine homogentisic acid\n  - Darkening with alkali/oxidation\n- **NOT on NBS**: Usually diagnosed in adulthood\n\n#### ğŸ¥— Treatment & Management\n- **No effective treatment**\n- **Symptomatic**: Pain management, joint replacement\n- **Vitamin C**: May slow pigment deposition\n- **Avoid**: High protein diet may worsen\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: HGD\n- **Prevalence**: 1:250,000-1,000,000\n- **High risk**: Slovakia, Dominican Republic\n\n#### ğŸ’ Board Pearls\n- Benign in childhood\n- One of Garrod's original IEM\n- Urine may be normal color when fresh\n- Joint replacement often needed\n\n---",
      "importance": 1
    },
    {
      "id": "carbohydrate-disorders",
      "title": "\udf6c CARBOHYDRATE DISORDERS",
      "content": "### Galactosemia (Classic) â­â­â­\n**High Board Yield - Know Types and Management\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Hepatomegaly** with jaundice\n2. **E. coli sepsis** risk\n3. **Cataracts** (oil drop)\n\n<details>\n<summary><strong>ğŸ¥ Clinical Features</strong> (Click to expand)</summary>\n\n- **Neonatal**: Poor feeding, vomiting, diarrhea after milk\n- **Hepatic**: Jaundice, hepatomegaly, cirrhosis\n- **Ocular**: Cataracts (reversible if early treatment)\n- **Renal**: Fanconi syndrome\n- **Neurologic**: ID despite treatment\n- **Ovarian**: POI in females (80%)\n- **Infection**: E. coli sepsis predisposition\n\n</details>\n\n<details>\n<summary><strong>ğŸ§ª Biochemistry & Testing</strong> (Click to expand)</summary>\n\n- **Defect**: Galactose-1-phosphate uridyltransferase (GALT)\n- **NBS**: Total galactose or GALT activity\n- **Confirmation**: \n  - GALT enzyme activity (RBC)\n  - Gal-1-P levels\n  - GALT gene sequencing\n- **False negatives**: If transfused before NBS\n\n</details>\n\n<details>\n<summary><strong>ğŸ¥— Treatment & Management</strong> (Click to expand)</summary>\n\n- **Diet**: STRICT galactose restriction\n  - No breast milk or regular formula\n  - Soy or elemental formula\n  - Avoid dairy, organ meats, some fruits/vegetables\n- **Monitoring**: \n  - Gal-1-P levels\n  - Ophthalmology\n  - Developmental assessment\n  - FSH/LH in females\n- **Calcium/Vit D**: Supplementation needed\n\n</details>\n\n<details>\n<summary><strong>ğŸ“ˆ Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Pattern**: Autosomal recessive\n- **Gene**: GALT (9p13)\n- **Prevalence**: 1:30,000-60,000\n- **Common mutations**: Q188R (European), S135L (African)\n- **Duarte variant**: D2 - benign, no treatment needed\n\n</details>\n\n#### ğŸ’ Board Pearls\n- Three types: Classic (GALT), Type II (GALK), Type III (GALE)\n- Despite diet, long-term complications common\n- POI â†’ egg donation often needed\n- Duarte/Classical compound het = intermediate phenotype\n- E. coli sepsis is classic presentation\n\n**[â¬†ï¸ Back to Top](#-quick-navigation)** | **[â¡ï¸ Next: Glycogen Storage Disease Type I](#glycogen-storage-disease-type-i-von-gierke-)**\n\n---\n\n### Glycogen Storage Disease Type I (Von Gierke) â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Severe hypoglycemia** with fasting\n2. **Hepatomegaly** (massive)\n3. **\"Doll-like\" face**\n\n#### ğŸ¥ Clinical Features\n- **Metabolic**: Severe fasting hypoglycemia, lactic acidosis\n- **Hepatic**: Massive hepatomegaly, adenomas\n- **Growth**: Short stature, delayed puberty\n- **Face**: Round \"doll-like\" facies\n- **Labs**: Hyperuricemia, hyperlipidemia\n- **Renal**: Nephromegaly, stones\n- **Bleeding**: Platelet dysfunction\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: \n  - Type Ia: Glucose-6-phosphatase (G6PC)\n  - Type Ib: G6P transporter (SLC37A4)\n- **Testing**: \n  - Hypoglycemia with â†‘ lactate\n  - NO ketones (distinguishing feature)\n  - Gene sequencing (replaced liver biopsy)\n- **Type Ib**: + Neutropenia, IBD\n\n#### ğŸ¥— Treatment & Management\n- **Cornstarch**: Every 3-4 hours (even overnight)\n- **Avoid**: Fasting >3-4 hours\n- **Diet**: High complex carbs, restrict simple sugars\n- **Monitor**: Glucose, lactate, lipids, uric acid\n- **Complications**: HCC surveillance (adenomas)\n- **Type Ib**: G-CSF for neutropenia\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Prevalence**: 1:100,000\n- **High risk**: Ashkenazi Jewish (Type Ia)\n\n#### ğŸ’ Board Pearls\n- Cannot fast >3-4 hours\n- Lactate â†‘ but NO ketones\n- Adenomas â†’ HCC risk\n- Normal intelligence\n- Type Ib has immune issues\n\n---\n\n### Glycogen Storage Disease Type II (Pompe) â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Hypertrophic cardiomyopathy** (infantile)\n2. **Profound hypotonia**\n3. **Elevated CK**\n\n#### ğŸ¥ Clinical Features\n**Infantile-onset**:\n- Profound hypotonia (\"floppy baby\")\n- Hypertrophic cardiomyopathy\n- Macroglossia\n- Hepatomegaly\n- Death <1 year if untreated\n\n**Late-onset**:\n- Progressive muscle weakness\n- Respiratory insufficiency\n- No cardiac involvement\n- Variable age of onset\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Acid Î±-glucosidase (GAA)\n- **NBS**: Some states screen\n- **Testing**: \n  - GAA enzyme activity (DBS, lymphocytes)\n  - CK elevated\n  - Gene sequencing\n  - Muscle biopsy (historical)\n\n#### ğŸ¥— Treatment & Management\n- **ERT**: Alglucosidase alfa (Myozyme/Lumizyme)\n  - Started ASAP for infantile\n  - Variable response\n  - CRIM status important\n- **Supportive**: Respiratory support, PT/OT\n- **Monitoring**: Echo, PFTs, motor function\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: GAA (17q25)\n- **Prevalence**: 1:40,000\n- **High risk**: African Americans, Taiwanese\n\n#### ğŸ’ Board Pearls\n- Only GSD with lysosomal defect\n- CRIM-negative â†’ poor ERT response\n- Respiratory > cardiac issues in late-onset\n- Part of NBS in some states\n\n---",
      "importance": 1
    },
    {
      "id": "lysosomal-storage-disorders",
      "title": "LYSOSOMAL STORAGE DISORDERS",
      "content": "### Gaucher Disease â­â­â­\n**Most Common LSD - High Yield for AJ Carrier Screening\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Hepatosplenomegaly** (massive)\n2. **Bone pain/crises**\n3. **Thrombocytopenia**\n\n#### ğŸ¥ Clinical Features by Type\n**Type 1 (Non-neuronopathic) - 90%**:\n- Hepatosplenomegaly\n- Anemia, thrombocytopenia\n- Bone disease (pain, AVN, fractures)\n- Gaucher cells in marrow\n- Normal intelligence\n- Parkinson disease risk (GBA carriers too)\n\n**Type 2 (Acute neuronopathic)**:\n- Onset <2 years\n- Severe neurodegeneration\n- Death by 2-4 years\n\n**Type 3 (Chronic neuronopathic)**:\n- Intermediate severity\n- Horizontal gaze palsy\n- Variable neurologic involvement\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Î²-glucocerebrosidase (GBA)\n- **Testing**: \n  - Enzyme activity (WBC, DBS)\n  - â†‘ Chitotriosidase\n  - Gene sequencing\n- **Carrier screening**: Standard in AJ panel\n\n#### ğŸ¥— Treatment & Management\n**Type 1**:\n- **ERT**: Imiglucerase, velaglucerase, taliglucerase\n- **SRT**: Miglustat, eliglustat\n- **Monitoring**: CBC, spleen size, bone imaging\n- **Avoid**: Splenectomy if possible\n\n**Types 2/3**: \n- ERT doesn't cross BBB\n- Supportive care\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: GBA (1q22)\n- **Prevalence**: \n  - General: 1:40,000\n  - Ashkenazi Jewish: 1:450\n- **Carrier frequency**:\n  - AJ: 1:15 (6%)\n  - General: 1:100\n- **Common AJ mutations**: N370S, 84GG, L444P, IVS2+1\n\n#### ğŸ’ Board Pearls\n- Most common LSD\n- N370S = Type 1 only (neuroprotective)\n- L444P homozygotes = neuronopathic\n- GBA carriers â†’ 5-fold â†‘ Parkinson risk\n- Pregnancy can worsen symptoms\n\n---\n\n### Tay-Sachs Disease â­â­â­\n**Classic AJ Carrier Screening - Know Well\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Cherry-red spot** on macula\n2. **Progressive neurodegeneration**\n3. **Exaggerated startle response**\n\n#### ğŸ¥ Clinical Features\n**Classic Infantile**:\n- Normal until 3-6 months\n- Loss of milestones\n- Hypotonia â†’ spasticity\n- Cherry-red spot (90%)\n- Seizures\n- Macrocephaly\n- Death by 2-5 years\n\n**Later-onset forms**:\n- Juvenile: 2-10 years onset\n- Adult: Motor neuron disease-like\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Hexosaminidase A (HEXA)\n- **Testing**: \n  - Enzyme activity (serum, WBC)\n  - Carrier: Enzyme + DNA\n  - Prenatal: CVS/amnio enzyme\n- **Pitfalls**: Pregnancy/OCP affect enzyme levels\n\n#### ğŸ¥— Treatment & Management\n- **No specific treatment**\n- **Supportive care**: \n  - Seizure management\n  - Feeding support\n  - Respiratory care\n- **Clinical trials**: Gene therapy ongoing\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: HEXA (15q23)\n- **Carrier frequency**:\n  - Ashkenazi Jewish: 1:30\n  - French Canadian: 1:30\n  - Cajun: 1:30\n  - Irish: 1:50\n  - General: 1:300\n\n#### ğŸ’ Board Pearls\n- Carrier screening success story (>90% reduction)\n- Pseudodeficiency alleles common\n- Sandhoff disease = Hex A + B deficiency\n- Test enzyme in pregnant/OCP users\n- 3 founder mutations in AJ (1278insTATC most common)\n\n---\n\n### Niemann-Pick Disease Types A/B â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Hepatosplenomegaly**\n2. **Cherry-red spot** (Type A)\n3. **Interstitial lung disease** (Type B)\n\n#### ğŸ¥ Clinical Features\n**Type A (Neuronopathic)**:\n- Onset <6 months\n- Massive hepatosplenomegaly\n- Neurodegeneration\n- Cherry-red spot (50%)\n- Death by 2-3 years\n\n**Type B (Non-neuronopathic)**:\n- Hepatosplenomegaly\n- Interstitial lung disease\n- Thrombocytopenia\n- Normal intelligence\n- Survival to adulthood\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Acid sphingomyelinase (SMPD1)\n- **Testing**: \n  - Enzyme activity\n  - â†‘ Sphingomyelin\n  - Gene sequencing\n- **Pathology**: Foam cells (Niemann-Pick cells)\n\n#### ğŸ¥— Treatment & Management\n- **Type B**: \n  - ERT in clinical trials\n  - Supportive care\n  - Monitor pulmonary function\n- **Type A**: Supportive only\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Carrier frequency (AJ)**: 1:80-100\n- **Common AJ mutations**: R496L, L302P, fsP330\n\n---\n\n### Niemann-Pick Disease Type C â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Vertical supranuclear gaze palsy**\n2. **Progressive neurodegeneration**\n3. **Hepatosplenomegaly** (variable)\n\n#### ğŸ¥ Clinical Features\n- **Classic (childhood)**: \n  - Ataxia\n  - Vertical gaze palsy (pathognomonic)\n  - Dysarthria, dysphagia\n  - Cognitive decline\n  - Psychiatric symptoms\n- **Variants**: Neonatal hepatitis, adult psychiatric\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: NPC1 (95%) or NPC2 (5%)\n- **Function**: Cholesterol trafficking\n- **Testing**: \n  - Filipin staining (fibroblasts)\n  - Oxysterol biomarkers\n  - Gene sequencing\n\n#### ğŸ¥— Treatment & Management\n- **Miglustat**: Substrate reduction\n- **Supportive**: Antiepileptics, psychiatry\n- **Experimental**: Cyclodextrin\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Prevalence**: 1:100,000\n- **Not part of AJ panel**\n\n---\n\n### Fabry Disease â­â­â­\n**X-linked LSD - Different from Others\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Acroparesthesias** (burning pain)\n2. **Angiokeratomas**\n3. **Corneal whorling**\n\n#### ğŸ¥ Clinical Features\n**Males (Classic)**:\n- Pain crises (hands/feet)\n- Angiokeratomas (bathing suit area)\n- Hypohidrosis\n- Corneal verticillata\n- Progressive renal failure\n- Cardiac (LVH, arrhythmias)\n- Stroke risk\n\n**Females**:\n- Variable (X-inactivation)\n- Corneal whorling common\n- Can be as severe as males\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Î±-galactosidase A (GLA)\n- **Testing**: \n  - Males: Enzyme activity\n  - Females: DNA (enzyme unreliable)\n  - â†‘ Gb3 in urine\n- **NBS**: Some states piloting\n\n#### ğŸ¥— Treatment & Management\n- **ERT**: Agalsidase beta (Fabrazyme)\n- **Oral chaperone**: Migalastat (amenable mutations)\n- **Symptomatic**: \n  - Pain management\n  - ACE inhibitors\n  - Dialysis/transplant\n- **Monitoring**: Renal, cardiac, neuro\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: X-linked\n- **Gene**: GLA (Xq22)\n- **Prevalence**: 1:40,000-60,000 males\n- **Later-onset variants**: More common\n\n#### ğŸ’ Board Pearls\n- Females are not just carriers\n- Enzyme testing unreliable in females\n- Corneal whorling doesn't affect vision\n- Later-onset cardiac variants common\n- Consider in young stroke\n\n---\n\n### Krabbe Disease â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Extreme irritability** (inconsolable crying)\n2. **Optic atrophy**\n3. **Rapid neurodegeneration**\n\n#### ğŸ¥ Clinical Features\n**Infantile (85-90%)**:\n- Normal at birth\n- Irritability by 3-6 months\n- Feeding difficulties\n- Stiffness, opisthotonus\n- Vision loss\n- Death by 2 years\n\n**Later-onset**:\n- Variable presentation\n- Gait abnormalities\n- Vision loss\n- Slower progression\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Galactocerebrosidase (GALC)\n- **Testing**: \n  - Enzyme activity\n  - â†‘ Psychosine (toxic)\n  - Gene sequencing\n- **NBS**: Few states (NY)\n\n#### ğŸ¥— Treatment & Management\n- **HSCT**: If presymptomatic or minimal symptoms\n- **Supportive care**: Most cases\n- **Timing critical**: Must treat before symptoms\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: GALC (14q31)\n- **Prevalence**: 1:100,000\n- **30kb deletion**: Common severe mutation\n\n#### ğŸ’ Board Pearls\n- No organomegaly (unlike other LSDs)\n- NBS controversial due to variants\n- HSCT only if presymptomatic\n- Psychosine is toxic metabolite\n\n---",
      "importance": 1
    },
    {
      "id": "mucopolysaccharidoses-mps",
      "title": "MUCOPOLYSACCHARIDOSES (MPS)",
      "content": "### MPS I (Hurler/Scheie Syndrome) â­â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Coarse facial features**\n2. **Corneal clouding**\n3. **Dysostosis multiplex**\n\n#### ğŸ¥ Clinical Features\n**Hurler (Severe)**:\n- Onset <2 years\n- Profound ID\n- Coarse features by 1 year\n- Corneal clouding\n- Organomegaly\n- Cardiac disease\n- Death by 10 without treatment\n\n**Scheie (Mild)**:\n- Normal intelligence\n- Joint stiffness\n- Corneal clouding\n- Cardiac valves\n- Normal lifespan\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Î±-L-iduronidase\n- **GAGs**: â†‘ Dermatan sulfate, â†‘ Heparan sulfate\n- **Testing**: \n  - Enzyme activity\n  - Urine GAGs (screening)\n  - Molecular confirmation\n- **X-rays**: Dysostosis multiplex\n\n#### ğŸ¥— Treatment & Management\n- **ERT**: Laronidase (Aldurazyme)\n  - Doesn't cross BBB\n  - Improves somatic features\n- **HSCT**: For Hurler syndrome\n  - Best <2 years\n  - Can preserve cognition\n- **Supportive**: ENT, ortho, cardio\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: IDUA (4p16.3)\n- **Prevalence**: 1:100,000\n- **Common mutations**: W402X, Q70X\n\n#### ğŸ’ Board Pearls\n- Hurler-Scheie = intermediate phenotype\n- HSCT + ERT may be combined\n- Corneal clouding in all forms\n- Most common MPS\n\n---\n\n### MPS II (Hunter Syndrome) â­â­â­\n**Only X-linked MPS\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **NO corneal clouding** (vs MPS I)\n2. **Pebbly skin lesions**\n3. **X-linked inheritance**\n\n#### ğŸ¥ Clinical Features\n**Severe form**:\n- Similar to Hurler but X-linked\n- Progressive ID\n- Behavioral issues\n- No corneal clouding\n- Characteristic skin lesions\n\n**Attenuated form**:\n- Normal/mild ID\n- Joint stiffness\n- Cardiac involvement\n- Survival to adulthood\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Iduronate-2-sulfatase (I2S)\n- **GAGs**: â†‘ Dermatan sulfate, â†‘ Heparan sulfate\n- **Testing**: \n  - Enzyme activity\n  - Molecular (deletions common)\n\n#### ğŸ¥— Treatment & Management\n- **ERT**: Idursulfase (Elaprase)\n- **No HSCT benefit** (unlike MPS I)\n- **Supportive care**\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: X-linked recessive\n- **Gene**: IDS (Xq28)\n- **Prevalence**: 1:100,000-170,000 males\n- **Carrier testing**: Important for families\n\n#### ğŸ’ Board Pearls\n- NO corneal clouding (key difference from MPS I)\n- Pebbly skin lesions (pathognomonic)\n- Behavioral issues common\n- Female carriers usually asymptomatic\n\n---\n\n### MPS III (Sanfilippo Syndrome) â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Severe behavioral problems**\n2. **Relatively mild somatic features**\n3. **Progressive ID**\n\n#### ğŸ¥ Clinical Features\n- **Topics**:\n  1. Developmental delay (1-3 years)\n  2. Behavioral issues (3-10 years)\n     - Hyperactivity\n     - Sleep disturbance\n     - Aggression\n  3. Neurodegeneration (>10 years)\n- **Mild coarse features**\n- **Normal height**\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Four different enzymes (A, B, C, D)\n- **GAG**: â†‘ Heparan sulfate only\n- **Testing**: Specific enzyme based on subtype\n\n#### ğŸ¥— Treatment & Management\n- **No approved treatment**\n- **Behavioral management**\n- **Clinical trials**: Gene therapy\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Prevalence**: 1:70,000 (all types)\n- **Type A most common**\n\n#### ğŸ’ Board Pearls\n- Most severe CNS involvement of MPS\n- Behavior > physical features\n- Four different subtypes (A-D)\n- No dermatan sulfate (unlike I, II)\n\n---",
      "importance": 1
    },
    {
      "id": "peroxisomal-fatty-acid-oxidation-disorders",
      "title": "PEROXISOMAL & FATTY ACID OXIDATION DISORDERS",
      "content": "### X-linked Adrenoleukodystrophy (X-ALD) â­â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Adrenal insufficiency**\n2. **Progressive white matter disease**\n3. **Very long chain fatty acids (VLCFA)**\n\n#### ğŸ¥ Clinical Phenotypes\n**Childhood cerebral (35%)**:\n- Normal until 4-10 years\n- Behavioral changes\n- Rapid neurodegeneration\n- Adrenal insufficiency\n- Death within 2-4 years\n\n**Adrenomyeloneuropathy (AMN)**:\n- Adult onset (20-30s)\n- Progressive paraparesis\n- Peripheral neuropathy\n- Adrenal insufficiency (70%)\n\n**Addison disease only (10%)**:\n- Isolated adrenal insufficiency\n- Can progress to other forms\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: ABCD1 (peroxisomal transporter)\n- **Testing**: \n  - â†‘ VLCFA (C26:0, C24:0)\n  - ACTH stimulation test\n  - Brain MRI\n  - Gene sequencing\n- **NBS**: Some states\n\n#### ğŸ¥— Treatment & Management\n- **Adrenal**: Hormone replacement\n- **Cerebral ALD**: \n  - HSCT if early (Loes score <9)\n  - Lorenzo's oil (questionable benefit)\n- **Monitoring**: \n  - Annual MRI (boys 3-12)\n  - Adrenal function\n- **Gene therapy**: Clinical trials\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: X-linked\n- **Gene**: ABCD1 (Xq28)\n- **Prevalence**: 1:20,000-50,000\n- **Penetrance**: Variable, even within families\n\n#### ğŸ’ Board Pearls\n- Female carriers can be symptomatic (AMN-like)\n- No genotype-phenotype correlation\n- Screen all males with Addison's\n- HSCT only helps if early cerebral\n- Different from neonatal ALD (Zellweger)\n\n---\n\n### Zellweger Syndrome â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Severe hypotonia** (neonatal)\n2. **Characteristic facies** (high forehead)\n3. **Hepatomegaly**\n\n#### ğŸ¥ Clinical Features\n- **Craniofacial**: High forehead, large fontanelles\n- **Neurologic**: Profound hypotonia, seizures\n- **Hepatic**: Hepatomegaly, jaundice\n- **Skeletal**: Stippled epiphyses\n- **Ocular**: Cataracts, glaucoma\n- **Death**: Usually <1 year\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: PEX genes (peroxisome biogenesis)\n- **Testing**: \n  - â†‘ VLCFA\n  - â†‘ Pipecolic acid\n  - Abnormal bile acids\n  - Plasmalogen deficiency\n\n#### ğŸ¥— Treatment & Management\n- **Supportive care only**\n- **No specific treatment**\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Genes**: PEX1 most common (70%)\n- **Prevalence**: 1:50,000\n\n#### ğŸ’ Board Pearls\n- Most severe peroxisomal disorder\n- Spectrum includes NALD, IRD\n- Stippled epiphyses on X-ray\n- Multiple peroxisomal functions affected\n\n---\n\n### Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD) â­â­â­\n**Most Common FAO Disorder\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Hypoketotic hypoglycemia**\n2. **Hepatomegaly** during crisis\n3. **\"SIDS-like\" presentation**\n\n#### ğŸ¥ Clinical Features\n- **Typical presentation**: \n  - Well until metabolic stress\n  - Vomiting, lethargy\n  - Hypoglycemia\n  - Can progress to coma/death\n- **Triggers**: Fasting, illness\n- **Age**: Usually 3-24 months\n- **Between episodes**: Normal\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: ACADM gene\n- **NBS**: â†‘ C8 (octanoylcarnitine)\n- **Confirmation**: \n  - Acylcarnitine profile\n  - Urine organic acids (crisis)\n  - Gene sequencing\n- **Common mutation**: c.985A>G (K329E)\n\n#### ğŸ¥— Treatment & Management\n- **Avoid fasting**: \n  - <6 months: q3-4h\n  - 6-12 months: q4-6h\n  - >1 year: max 8-10h\n- **Emergency protocol**: \n  - IV dextrose for illness\n  - Written plan for families\n- **Diet**: Normal fat content OK\n- **Carnitine**: If deficient\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: ACADM (1p31)\n- **Prevalence**: 1:15,000\n- **Carrier frequency**: 1:60 (Northern European)\n- **NBS success**: Prevents most deaths\n\n#### ğŸ’ Board Pearls\n- #1 cause of \"near-miss SIDS\"\n- K329E mutation in 80% of alleles\n- Normal between episodes\n- Excellent prognosis if fasting avoided\n- Some never have symptoms (NBS finding)\n\n---",
      "importance": 1
    },
    {
      "id": "metal-transport-disorders",
      "title": "METAL TRANSPORT DISORDERS",
      "content": "### Wilson Disease â­â­â­\n**Treatable Cause of Liver Disease + Neuropsychiatric\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Kayser-Fleischer rings**\n2. **Liver disease** (varies)\n3. **Neuropsychiatric symptoms**\n\n#### ğŸ¥ Clinical Features\n**Hepatic (40%)**:\n- Acute hepatitis\n- Chronic hepatitis\n- Cirrhosis\n- Fulminant hepatic failure\n\n**Neurologic (40%)**:\n- Tremor (wing-beating)\n- Dystonia\n- Dysarthria\n- Dysphagia\n- Parkinsonism\n\n**Psychiatric (20%)**:\n- Personality changes\n- Depression\n- Psychosis\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: ATP7B (copper transport)\n- **Testing**: \n  - â†“ Ceruloplasmin (<20)\n  - â†‘ 24hr urine copper (>100)\n  - â†‘ Hepatic copper\n  - K-F rings (slit lamp)\n- **Gene sequencing**: >500 mutations\n\n#### ğŸ¥— Treatment & Management\n- **Chelation**: \n  - Penicillamine\n  - Trientine\n  - Zinc (blocks absorption)\n- **Diet**: Avoid high copper foods\n- **Monitoring**: 24hr urine copper\n- **Liver transplant**: If fulminant failure\n- **Family screening**: Essential\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: ATP7B (13q14)\n- **Prevalence**: 1:30,000\n- **Age of onset**: 6-45 years\n- **High risk**: Sardinia, Japan\n\n#### ğŸ’ Board Pearls\n- K-F rings absent in 50% with liver disease\n- Low alkaline phosphatase in fulminant failure\n- Screen siblings (even if asymptomatic)\n- Pregnancy: Continue treatment\n- Treatable â†’ great prognosis if caught early\n\n---\n\n### Menkes Disease â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Kinky/steely hair**\n2. **Severe neurodegeneration**\n3. **Connective tissue abnormalities**\n\n#### ğŸ¥ Clinical Features\n- **Hair**: Sparse, brittle, twisted (pili torti)\n- **Neurologic**: Hypotonia, seizures, ID\n- **Vascular**: Tortuous vessels, aneurysms\n- **Skeletal**: Osteoporosis, fractures\n- **Skin**: Lax, doughy\n- **Temperature instability**\n- **Death**: Usually by 3 years\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: ATP7A (copper transport)\n- **Testing**: \n  - â†“ Serum copper\n  - â†“ Ceruloplasmin\n  - Gene sequencing\n- **Prenatal**: Copper in CVS\n\n#### ğŸ¥— Treatment & Management\n- **Copper histidine**: Subcutaneous\n  - Must start <2 months\n  - Limited benefit if started late\n- **Supportive care**\n- **Genetic counseling**: X-linked\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: X-linked recessive\n- **Gene**: ATP7A (Xq21.1)\n- **Prevalence**: 1:100,000-250,000\n- **Allelic**: Occipital horn syndrome (milder)\n\n#### ğŸ’ Board Pearls\n- Opposite of Wilson (copper deficiency)\n- Hair abnormalities pathognomonic\n- Female carriers: 50% have pili torti\n- Early treatment critical but limited benefit\n\n---",
      "importance": 1
    }
  ],
  "objectives": [],
  "sectionCount": 17,
  "rawContent": "# Topic 5: Inborn Errors of Metabolism - Comprehensive Board Study Guide\n\n## ğŸ“– Quick Navigation\n\n**[â¬†ï¸ Back to Master Index](study-guide-master-index.md)** | **[â¬…ï¸ Previous: Neurological Disorders](topic4-neurological-developmental.md)** | **[â¡ï¸ Next: Final Topic](topic6-final-topic.md)**\n\n### ğŸ“‹ Table of Contents\n- [ğŸ¯ Learning Objectives](#-learning-objectives)\n- [ğŸ“Š Overview of Metabolic Disorders](#-overview-of-metabolic-disorders)\n- [ğŸ§¬ Amino Acid Disorders](#-amino-acid-disorders)\n  - [Phenylketonuria (PKU) â­â­â­](#phenylketonuria-pku-)\n  - [Homocystinuria â­â­](#homocystinuria-)\n  - [Tyrosinemia Type I â­â­](#tyrosinemia-type-i-)\n- [ğŸ§ª Organic Acidemias](#-organic-acidemias)\n  - [Methylmalonic Acidemia (MMA) â­â­â­](#methylmalonic-acidemia-mma-)\n  - [Propionic Acidemia â­â­](#propionic-acidemia-)\n  - [Maple Syrup Urine Disease (MSUD) â­â­](#maple-syrup-urine-disease-msud-)\n- [ğŸ¬ Carbohydrate Disorders](#-carbohydrate-disorders)\n  - [Galactosemia (Classic) â­â­â­](#galactosemia-classic-)\n  - [Glycogen Storage Disease Type I â­â­](#glycogen-storage-disease-type-i-von-gierke-)\n  - [Glycogen Storage Disease Type II â­â­](#glycogen-storage-disease-type-ii-pompe-)\n- [ğŸ§¬ Lysosomal Storage Disorders](#-lysosomal-storage-disorders)\n  - [Gaucher Disease â­â­â­](#gaucher-disease-)\n  - [Tay-Sachs Disease â­â­â­](#tay-sachs-disease-)\n  - [Fabry Disease â­â­â­](#fabry-disease-)\n- [ğŸ§¬ Mucopolysaccharidoses (MPS)](#-mucopolysaccharidoses-mps)\n- [ğŸ§¬ Peroxisomal & Fatty Acid Oxidation Disorders](#-peroxisomal--fatty-acid-oxidation-disorders)\n- [ğŸ§¬ Metal Transport Disorders](#-metal-transport-disorders)\n- [ğŸ§¬ Other Key Metabolic Disorders](#-other-key-metabolic-disorders)\n- [ğŸ“‹ Study Aids & Mnemonics](#-study-aids--mnemonics)\n- [ğŸ¯ High-Yield Board Facts](#-high-yield-board-facts)\n- [ğŸ“ Practice Questions](#-practice-questions)\n- [âœ… Topic 5 Completion Checklist](#-topic-5-completion-checklist)\n\n### ğŸ” Quick Disorder Lookup\n| Disorder | Gene/Defect | Key Features | Inheritance | NBS |\n|----------|-------------|--------------|-------------|-----|\n| **PKU** | PAH | ID without treatment, musty odor | AR | Yes |\n| **Galactosemia** | GALT | Liver disease, E. coli sepsis | AR | Yes |\n| **MCAD** | ACADM | Hypoketotic hypoglycemia | AR | Yes |\n| **Gaucher** | GBA | Hepatosplenomegaly, bone disease | AR | No |\n| **Tay-Sachs** | HEXA | Cherry-red spot, neurodegeneration | AR | No |\n| **Fabry** | GLA | Acroparesthesias, angiokeratomas | X-linked | Some |\n| **Hunter (MPS II)** | IDS | NO corneal clouding | X-linked | No |\n| **Wilson** | ATP7B | K-F rings, liver disease | AR | No |\n| **FH** | LDLR | Very high LDL, xanthomas | AD | No |\n\n### ğŸ† Board Exam Domain Coverage\n- **Primary Domain:** Clinical Genetics (40-50%)\n- **Secondary Domains:** General Genetics/Genomics (15-25%)\n- **Difficulty Level:** Intermediate to Advanced\n- **Estimated Study Time:** 15-18 hours\n- **Last Updated:** July 2025\n\n---\n\n## ğŸ¯ Learning Objectives\n\nBy the end of this topic, you should be able to:\n\n1. **Identify** which metabolic disorders are included in newborn screening panels and their follow-up protocols\n2. **Calculate** carrier risks for metabolic disorders in specific populations (Ashkenazi Jewish, Finnish, etc.)\n3. **Counsel** families on dietary management for PKU, galactosemia, and other treatable conditions\n4. **Distinguish** between different types of metabolic disorders based on clinical presentation and biochemical findings\n5. **Explain** enzyme replacement therapy options and their implications for genetic counseling\n6. **Apply** consanguinity risk calculations for autosomal recessive metabolic disorders\n7. **Recognize** metabolic emergencies and appropriate management protocols\n8. **Compare** population-based carrier screening programs (Tay-Sachs, Gaucher) and their effectiveness\n9. **Interpret** biochemical test results including amino acid profiles and enzyme activity levels\n10. **Describe** inheritance patterns and recurrence risks for all major metabolic disorders\n11. **Evaluate** treatment compliance challenges and psychosocial impacts on families\n12. **Demonstrate** understanding of metabolic pathways and their disruption in disease states\n\n---\n\n## ğŸ“Š Overview of Metabolic Disorders\n\n<details>\n<summary><strong>ğŸ“Š Classification by Pathway</strong> (Click to expand)</summary>\n\n### Classification by Pathway\n1. **Small molecule diseases** - accumulation of toxic metabolites\n   - Amino acid disorders\n   - Organic acidemias\n   - Urea cycle defects\n2. **Large molecule diseases** - storage of complex molecules\n   - Lysosomal storage disorders\n   - Mucopolysaccharidoses\n   - Glycogen storage diseases\n3. **Energy metabolism defects**\n   - Fatty acid oxidation disorders\n   - Mitochondrial disorders\n\n### Key Counseling Concepts\n- **Newborn screening**: Early detection â†’ prevention of irreversible damage\n- **Dietary management**: Lifelong compliance challenges\n- **Carrier screening**: Population-specific risks\n- **Enzyme replacement**: Cost, access, effectiveness\n- **Prenatal diagnosis**: Options and timing\n- **Emergency protocols**: Metabolic crisis management\n\n</details>\n\n**[â¬†ï¸ Back to Top](#-quick-navigation)**\n\n---\n\n## ğŸ§¬ AMINO ACID DISORDERS\n\n### Phenylketonuria (PKU) â­â­â­\n**Most Common Amino Acid Disorder - High Board Yield\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Intellectual disability** if untreated\n2. **Musty body odor**\n3. **Fair skin/hair** (decreased pigmentation)\n\n<details>\n<summary><strong>ğŸ¥ Clinical Features</strong> (Click to expand)</summary>\n\n- **Neurological**: Progressive ID without treatment, seizures, behavioral problems\n- **Dermatologic**: Eczema, decreased melanin â†’ fair complexion\n- **Metabolic**: Elevated phenylalanine, low tyrosine\n- **Other**: Musty/mousy odor (phenylacetic acid in urine/sweat)\n\n</details>\n\n<details>\n<summary><strong>ğŸ§ª Biochemistry & Testing</strong> (Click to expand)</summary>\n\n- **Defect**: Phenylalanine hydroxylase (PAH) deficiency\n- **Pathway**: Phenylalanine â†’ Tyrosine (blocked)\n- **NBS**: Tandem MS - elevated phenylalanine\n- **Confirmation**: Plasma amino acids, PAH gene sequencing\n- **Classification**:\n  - Classic PKU: Phe >1200 Î¼mol/L\n  - Moderate PKU: Phe 600-1200 Î¼mol/L\n  - Mild PKU: Phe 360-600 Î¼mol/L\n  - Mild hyperphe: Phe 120-360 Î¼mol/L\n\n</details>\n\n<details>\n<summary><strong>ğŸ¥— Treatment & Management</strong> (Click to expand)</summary>\n\n- **Diet**: Low phenylalanine diet (avoid high protein foods)\n- **Formula**: Phe-free medical foods\n- **Monitoring**: Regular Phe levels\n- **New therapies**: \n  - Sapropterin (Kuvan) - BH4 cofactor supplementation\n  - Pegvaliase (Palynziq) - enzyme substitution therapy\n- **Goal Phe levels**: \n  - <12 years: 120-360 Î¼mol/L\n  - >12 years: 120-600 Î¼mol/L\n  - Pregnancy: 120-360 Î¼mol/L\n\n</details>\n\n<details>\n<summary><strong>ğŸ‘¶ Maternal PKU Syndrome</strong> (Click to expand)</summary>\n\n- **Risks if Phe >360 Î¼mol/L during pregnancy**:\n  - Microcephaly (73%)\n  - ID/DD (92%)\n  - Congenital heart disease (12%)\n  - IUGR (40%)\n- **Prevention**: Strict diet control BEFORE conception\n- **Monitoring**: Weekly Phe levels during pregnancy\n\n</details>\n\n<details>\n<summary><strong>ğŸ“ˆ Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Pattern**: Autosomal recessive\n- **Gene**: PAH (12q23.2)\n- **Prevalence**: 1:10,000-15,000 (US)\n- **Carrier frequency**: \n  - General: 1:50-60\n  - Turkish: 1:25\n  - Irish: 1:30\n\n</details>\n\n#### ğŸ’ Board Pearls\n- Cannot test Phe/Tyr ratio if on birth control or pregnant\n- Most common inborn error of amino acid metabolism\n- All 50 states include PKU in NBS\n- Offspring of PKU mothers: 100% carriers, at risk for maternal PKU effects\n- Compliance challenges increase in adolescence\n\n**[â¬†ï¸ Back to Top](#-quick-navigation)** | **[â¡ï¸ Next: Homocystinuria](#homocystinuria-)**\n\n---\n\n### Homocystinuria â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Ectopia lentis** (downward lens dislocation)\n2. **Marfanoid habitus**\n3. **Thromboembolism risk**\n\n<details>\n<summary><strong>ğŸ¥ Clinical Features</strong> (Click to expand)</summary>\n\n- **Ocular**: Ectopia lentis (85%), myopia, glaucoma\n- **Skeletal**: Tall stature, arachnodactyly, scoliosis, osteoporosis\n- **Vascular**: Thromboembolism (50% by age 30)\n- **Neurologic**: ID variable, seizures, psychiatric symptoms\n- **Other**: Fair complexion, malar flush\n\n</details>\n\n<details>\n<summary><strong>ğŸ§ª Biochemistry & Testing</strong> (Click to expand)</summary>\n\n- **Defect**: Cystathionine Î²-synthase (CBS) deficiency (most common)\n- **Pathway**: Homocysteine â†’ Cystathionine (blocked)\n- **NBS**: Not universally screened\n- **Testing**: \n  - Plasma homocysteine (elevated)\n  - Plasma methionine (elevated in CBS deficiency)\n  - Urine homocystine\n- **Other causes**: MTHFR deficiency, B12 metabolism defects\n\n</details>\n\n<details>\n<summary><strong>ğŸ¥— Treatment & Management</strong> (Click to expand)</summary>\n\n- **B6 responsive (50%)**: High-dose pyridoxine\n- **B6 non-responsive**: \n  - Low methionine diet\n  - Cystine supplementation\n  - Betaine (lowers homocysteine)\n- **Thrombosis prevention**: Aspirin, avoid surgery/dehydration\n- **Folate/B12**: For other forms\n\n</details>\n\n<details>\n<summary><strong>ğŸ“ˆ Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Pattern**: Autosomal recessive\n- **Gene**: CBS (21q22.3)\n- **Prevalence**: 1:200,000-335,000\n- **Note**: Heterozygotes may have mild â†‘ homocysteine â†’ cardiovascular risk\n\n</details>\n\n#### ğŸ’ Board Pearls\n- Lens dislocation: DOWN and OUT (vs Marfan: UP)\n- Major cause of preventable ID if B6 responsive\n- Screen before surgery due to thrombosis risk\n- Can be missed on NBS if mild or late-onset\n\n**[â¬†ï¸ Back to Top](#-quick-navigation)** | **[â¡ï¸ Next: Tyrosinemia Type I](#tyrosinemia-type-i-)**\n\n---\n\n### Tyrosinemia Type I â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Liver failure** in infancy\n2. **Renal tubular dysfunction**\n3. **\"Cabbage-like\" odor**\n\n<details>\n<summary><strong>ğŸ¥ Clinical Features</strong> (Click to expand)</summary>\n\n- **Hepatic**: Acute liver failure, cirrhosis, hepatocellular carcinoma\n- **Renal**: Fanconi syndrome, rickets\n- **Neurologic**: Painful crises (peripheral neuropathy)\n- **Other**: Failure to thrive, coagulopathy\n\n</details>\n\n<details>\n<summary><strong>ğŸ§ª Biochemistry & Testing</strong> (Click to expand)</summary>\n\n- **Defect**: Fumarylacetoacetate hydrolase (FAH) deficiency\n- **Pathway**: Tyrosine degradation pathway (final step blocked)\n- **NBS**: Succinylacetone (pathognomonic)\n- **Testing**: \n  - Urine organic acids: succinylacetone\n  - Plasma amino acids: â†‘ tyrosine\n  - AFP: markedly elevated\n\n</details>\n\n<details>\n<summary><strong>ğŸ¥— Treatment & Management</strong> (Click to expand)</summary>\n\n- **NTBC (nitisinone)**: Blocks upstream enzyme\n- **Diet**: Low tyrosine, low phenylalanine\n- **Monitoring**: AFP for HCC surveillance\n- **Liver transplant**: If medical management fails\n\n</details>\n\n<details>\n<summary><strong>ğŸ“ˆ Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Pattern**: Autosomal recessive\n- **Gene**: FAH (15q25.1)\n- **Prevalence**: 1:100,000\n- **High risk**: French Canadian (Saguenay) 1:1,850\n\n</details>\n\n#### ğŸ’ Board Pearls\n- Dramatically improved prognosis with NTBC\n- Succinylacetone is pathognomonic\n- High HCC risk even with treatment\n- Type II: eye/skin findings; Type III: mild ID\n\n**[â¬†ï¸ Back to Top](#-quick-navigation)** | **[â¡ï¸ Next: Organic Acidemias](#-organic-acidemias)**\n\n---\n\n## ğŸ§ª ORGANIC ACIDEMIAS\n\n### Methylmalonic Acidemia (MMA) â­â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Metabolic acidosis** with anion gap\n2. **Hyperammonemia**\n3. **Elevated C3 on acylcarnitine profile**\n\n#### ğŸ¥ Clinical Features\n- **Acute presentation**: Lethargy, vomiting, dehydration\n- **Metabolic**: Ketoacidosis, hyperammonemia\n- **Neurologic**: Encephalopathy, developmental delays\n- **Hematologic**: Pancytopenia\n- **Renal**: Progressive CKD\n- **Long-term**: Basal ganglia strokes\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Methylmalonyl-CoA mutase OR cobalamin metabolism\n- **NBS**: â†‘ C3 (propionylcarnitine)\n- **Confirmation**: \n  - Urine organic acids: methylmalonic acid\n  - Plasma amino acids: â†‘ glycine\n  - B12 levels\n- **Subtypes**: \n  - mutâ°: No enzyme activity\n  - mutâ»: Reduced enzyme activity\n  - cbl A-G: Cobalamin metabolism defects\n\n#### ğŸ¥— Treatment & Management\n- **Acute**: IV glucose, bicarbonate, carnitine\n- **Chronic**: \n  - Protein restriction (1-1.5 g/kg/day)\n  - Medical formula\n  - L-carnitine supplementation\n  - B12 (responsive forms)\n- **Emergency protocol**: Written plan for illness\n- **Transplant**: Liver or combined liver-kidney\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Genes**: MUT, MMAA-MMAB, others\n- **Prevalence**: 1:50,000-120,000\n- **High risk populations**: Saudi (1:3,500)\n\n#### ğŸ’ Board Pearls\n- Some forms B12 responsive - always trial\n- Combined with homocystinuria = cbl C defect\n- Risk of metabolic stroke during crisis\n- Sibling recurrence: 25%\n\n---\n\n### Propionic Acidemia â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Metabolic acidosis** with ketosis\n2. **Hyperammonemia**\n3. **Cardiomyopathy** (late complication)\n\n#### ğŸ¥ Clinical Features\n- **Acute**: Similar to MMA - lethargy, vomiting\n- **Metabolic**: Ketoacidosis, hyperammonemia, hypoglycemia\n- **Neurologic**: Seizures, basal ganglia changes\n- **Cardiac**: Dilated cardiomyopathy, arrhythmias\n- **GI**: Pancreatitis\n- **Immunologic**: T-cell dysfunction\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Propionyl-CoA carboxylase\n- **NBS**: â†‘ C3\n- **Confirmation**: \n  - Urine organic acids: 3-hydroxypropionate, methylcitrate\n  - Enzyme assay in fibroblasts\n\n#### ğŸ¥— Treatment & Management\n- **Similar to MMA**: Protein restriction, medical formula\n- **Biotin**: Trial (rarely responsive)\n- **Avoid**: Propiogenic amino acids (Val, Ile, Met, Thr)\n- **Cardiac monitoring**: Echo, EKG\n- **Liver transplant**: Consideration\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Genes**: PCCA, PCCB\n- **Prevalence**: 1:100,000\n- **High risk**: Saudi Arabia, Amish\n\n---\n\n### Maple Syrup Urine Disease (MSUD) â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Sweet maple syrup odor** (urine, cerumen)\n2. **Encephalopathy** in newborn period\n3. **Elevated branched-chain amino acids**\n\n#### ğŸ¥ Clinical Features\n- **Classic form (85%)**: \n  - Normal at birth\n  - Poor feeding by 2-3 days\n  - Encephalopathy by 4-5 days\n  - Characteristic odor\n- **Neurologic**: Alternating hyper/hypotonia, seizures\n- **Metabolic**: Ketoacidosis, hypoglycemia\n- **Intermediate/intermittent**: Later onset, triggered by illness\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Branched-chain Î±-ketoacid dehydrogenase complex\n- **NBS**: â†‘ leucine, isoleucine, valine\n- **Confirmation**: \n  - Plasma amino acids: â†‘ BCAAs\n  - Urine organic acids: branched-chain ketoacids\n  - Alloisoleucine (pathognomonic)\n\n#### ğŸ¥— Treatment & Management\n- **Acute**: Hemodialysis may be needed\n- **Diet**: Restrict BCAAs (leucine most toxic)\n- **Medical formula**: BCAA-free\n- **Thiamine**: Trial (responsive forms exist)\n- **Monitoring**: Frequent amino acid levels\n- **Emergency**: IV glucose, avoid catabolism\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Genes**: BCKDHA, BCKDHB, DBT, DLD\n- **Prevalence**: 1:185,000\n- **High risk**: Old Order Mennonites (1:380)\n\n#### ğŸ’ Board Pearls\n- Can have normal intelligence if well-controlled\n- Leucine is most neurotoxic BCAA\n- Smell may be subtle - check earwax\n- Metabolic crisis with minor illness\n\n---\n\n### Isovaleric Acidemia â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **\"Sweaty feet\" odor**\n2. **Metabolic acidosis**\n3. **Elevated C5 on NBS**\n\n#### ğŸ¥ Clinical Features\n- **Acute neonatal**: Vomiting, lethargy, acidosis\n- **Chronic intermittent**: Episodes during illness\n- **Odor**: Characteristic \"sweaty feet\" smell\n- **Neurologic**: Variable developmental outcome\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Isovaleryl-CoA dehydrogenase\n- **NBS**: â†‘ C5 (isovalerylcarnitine)\n- **Confirmation**: \n  - Urine organic acids: isovalerylglycine\n  - Plasma acylcarnitines\n\n#### ğŸ¥— Treatment & Management\n- **Diet**: Leucine restriction (mild)\n- **Carnitine**: Enhances excretion\n- **Glycine**: Conjugation therapy\n- **Avoid**: Fasting, high protein\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: IVD\n- **Prevalence**: 1:250,000\n\n---\n\n### Alkaptonuria â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Black urine** (on standing/alkalinization)\n2. **Ochronosis** (dark pigmentation)\n3. **Arthritis** in adulthood\n\n#### ğŸ¥ Clinical Features\n- **Urine**: Darkens on standing or with alkali\n- **Ochronosis**: Blue-black cartilage pigmentation\n  - Ear cartilage\n  - Sclera\n  - Heart valves\n- **Arthritis**: Large joints, spine (30s-40s)\n- **Cardiac**: Valve disease, CAD\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Homogentisate 1,2-dioxygenase\n- **Testing**: \n  - Urine homogentisic acid\n  - Darkening with alkali/oxidation\n- **NOT on NBS**: Usually diagnosed in adulthood\n\n#### ğŸ¥— Treatment & Management\n- **No effective treatment**\n- **Symptomatic**: Pain management, joint replacement\n- **Vitamin C**: May slow pigment deposition\n- **Avoid**: High protein diet may worsen\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: HGD\n- **Prevalence**: 1:250,000-1,000,000\n- **High risk**: Slovakia, Dominican Republic\n\n#### ğŸ’ Board Pearls\n- Benign in childhood\n- One of Garrod's original IEM\n- Urine may be normal color when fresh\n- Joint replacement often needed\n\n---\n\n## ğŸ¬ CARBOHYDRATE DISORDERS\n\n### Galactosemia (Classic) â­â­â­\n**High Board Yield - Know Types and Management\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Hepatomegaly** with jaundice\n2. **E. coli sepsis** risk\n3. **Cataracts** (oil drop)\n\n<details>\n<summary><strong>ğŸ¥ Clinical Features</strong> (Click to expand)</summary>\n\n- **Neonatal**: Poor feeding, vomiting, diarrhea after milk\n- **Hepatic**: Jaundice, hepatomegaly, cirrhosis\n- **Ocular**: Cataracts (reversible if early treatment)\n- **Renal**: Fanconi syndrome\n- **Neurologic**: ID despite treatment\n- **Ovarian**: POI in females (80%)\n- **Infection**: E. coli sepsis predisposition\n\n</details>\n\n<details>\n<summary><strong>ğŸ§ª Biochemistry & Testing</strong> (Click to expand)</summary>\n\n- **Defect**: Galactose-1-phosphate uridyltransferase (GALT)\n- **NBS**: Total galactose or GALT activity\n- **Confirmation**: \n  - GALT enzyme activity (RBC)\n  - Gal-1-P levels\n  - GALT gene sequencing\n- **False negatives**: If transfused before NBS\n\n</details>\n\n<details>\n<summary><strong>ğŸ¥— Treatment & Management</strong> (Click to expand)</summary>\n\n- **Diet**: STRICT galactose restriction\n  - No breast milk or regular formula\n  - Soy or elemental formula\n  - Avoid dairy, organ meats, some fruits/vegetables\n- **Monitoring**: \n  - Gal-1-P levels\n  - Ophthalmology\n  - Developmental assessment\n  - FSH/LH in females\n- **Calcium/Vit D**: Supplementation needed\n\n</details>\n\n<details>\n<summary><strong>ğŸ“ˆ Inheritance & Statistics</strong> (Click to expand)</summary>\n\n- **Pattern**: Autosomal recessive\n- **Gene**: GALT (9p13)\n- **Prevalence**: 1:30,000-60,000\n- **Common mutations**: Q188R (European), S135L (African)\n- **Duarte variant**: D2 - benign, no treatment needed\n\n</details>\n\n#### ğŸ’ Board Pearls\n- Three types: Classic (GALT), Type II (GALK), Type III (GALE)\n- Despite diet, long-term complications common\n- POI â†’ egg donation often needed\n- Duarte/Classical compound het = intermediate phenotype\n- E. coli sepsis is classic presentation\n\n**[â¬†ï¸ Back to Top](#-quick-navigation)** | **[â¡ï¸ Next: Glycogen Storage Disease Type I](#glycogen-storage-disease-type-i-von-gierke-)**\n\n---\n\n### Glycogen Storage Disease Type I (Von Gierke) â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Severe hypoglycemia** with fasting\n2. **Hepatomegaly** (massive)\n3. **\"Doll-like\" face**\n\n#### ğŸ¥ Clinical Features\n- **Metabolic**: Severe fasting hypoglycemia, lactic acidosis\n- **Hepatic**: Massive hepatomegaly, adenomas\n- **Growth**: Short stature, delayed puberty\n- **Face**: Round \"doll-like\" facies\n- **Labs**: Hyperuricemia, hyperlipidemia\n- **Renal**: Nephromegaly, stones\n- **Bleeding**: Platelet dysfunction\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: \n  - Type Ia: Glucose-6-phosphatase (G6PC)\n  - Type Ib: G6P transporter (SLC37A4)\n- **Testing**: \n  - Hypoglycemia with â†‘ lactate\n  - NO ketones (distinguishing feature)\n  - Gene sequencing (replaced liver biopsy)\n- **Type Ib**: + Neutropenia, IBD\n\n#### ğŸ¥— Treatment & Management\n- **Cornstarch**: Every 3-4 hours (even overnight)\n- **Avoid**: Fasting >3-4 hours\n- **Diet**: High complex carbs, restrict simple sugars\n- **Monitor**: Glucose, lactate, lipids, uric acid\n- **Complications**: HCC surveillance (adenomas)\n- **Type Ib**: G-CSF for neutropenia\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Prevalence**: 1:100,000\n- **High risk**: Ashkenazi Jewish (Type Ia)\n\n#### ğŸ’ Board Pearls\n- Cannot fast >3-4 hours\n- Lactate â†‘ but NO ketones\n- Adenomas â†’ HCC risk\n- Normal intelligence\n- Type Ib has immune issues\n\n---\n\n### Glycogen Storage Disease Type II (Pompe) â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Hypertrophic cardiomyopathy** (infantile)\n2. **Profound hypotonia**\n3. **Elevated CK**\n\n#### ğŸ¥ Clinical Features\n**Infantile-onset**:\n- Profound hypotonia (\"floppy baby\")\n- Hypertrophic cardiomyopathy\n- Macroglossia\n- Hepatomegaly\n- Death <1 year if untreated\n\n**Late-onset**:\n- Progressive muscle weakness\n- Respiratory insufficiency\n- No cardiac involvement\n- Variable age of onset\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Acid Î±-glucosidase (GAA)\n- **NBS**: Some states screen\n- **Testing**: \n  - GAA enzyme activity (DBS, lymphocytes)\n  - CK elevated\n  - Gene sequencing\n  - Muscle biopsy (historical)\n\n#### ğŸ¥— Treatment & Management\n- **ERT**: Alglucosidase alfa (Myozyme/Lumizyme)\n  - Started ASAP for infantile\n  - Variable response\n  - CRIM status important\n- **Supportive**: Respiratory support, PT/OT\n- **Monitoring**: Echo, PFTs, motor function\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: GAA (17q25)\n- **Prevalence**: 1:40,000\n- **High risk**: African Americans, Taiwanese\n\n#### ğŸ’ Board Pearls\n- Only GSD with lysosomal defect\n- CRIM-negative â†’ poor ERT response\n- Respiratory > cardiac issues in late-onset\n- Part of NBS in some states\n\n---\n\n## ğŸ§¬ LYSOSOMAL STORAGE DISORDERS\n\n### Gaucher Disease â­â­â­\n**Most Common LSD - High Yield for AJ Carrier Screening\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Hepatosplenomegaly** (massive)\n2. **Bone pain/crises**\n3. **Thrombocytopenia**\n\n#### ğŸ¥ Clinical Features by Type\n**Type 1 (Non-neuronopathic) - 90%**:\n- Hepatosplenomegaly\n- Anemia, thrombocytopenia\n- Bone disease (pain, AVN, fractures)\n- Gaucher cells in marrow\n- Normal intelligence\n- Parkinson disease risk (GBA carriers too)\n\n**Type 2 (Acute neuronopathic)**:\n- Onset <2 years\n- Severe neurodegeneration\n- Death by 2-4 years\n\n**Type 3 (Chronic neuronopathic)**:\n- Intermediate severity\n- Horizontal gaze palsy\n- Variable neurologic involvement\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Î²-glucocerebrosidase (GBA)\n- **Testing**: \n  - Enzyme activity (WBC, DBS)\n  - â†‘ Chitotriosidase\n  - Gene sequencing\n- **Carrier screening**: Standard in AJ panel\n\n#### ğŸ¥— Treatment & Management\n**Type 1**:\n- **ERT**: Imiglucerase, velaglucerase, taliglucerase\n- **SRT**: Miglustat, eliglustat\n- **Monitoring**: CBC, spleen size, bone imaging\n- **Avoid**: Splenectomy if possible\n\n**Types 2/3**: \n- ERT doesn't cross BBB\n- Supportive care\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: GBA (1q22)\n- **Prevalence**: \n  - General: 1:40,000\n  - Ashkenazi Jewish: 1:450\n- **Carrier frequency**:\n  - AJ: 1:15 (6%)\n  - General: 1:100\n- **Common AJ mutations**: N370S, 84GG, L444P, IVS2+1\n\n#### ğŸ’ Board Pearls\n- Most common LSD\n- N370S = Type 1 only (neuroprotective)\n- L444P homozygotes = neuronopathic\n- GBA carriers â†’ 5-fold â†‘ Parkinson risk\n- Pregnancy can worsen symptoms\n\n---\n\n### Tay-Sachs Disease â­â­â­\n**Classic AJ Carrier Screening - Know Well\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Cherry-red spot** on macula\n2. **Progressive neurodegeneration**\n3. **Exaggerated startle response**\n\n#### ğŸ¥ Clinical Features\n**Classic Infantile**:\n- Normal until 3-6 months\n- Loss of milestones\n- Hypotonia â†’ spasticity\n- Cherry-red spot (90%)\n- Seizures\n- Macrocephaly\n- Death by 2-5 years\n\n**Later-onset forms**:\n- Juvenile: 2-10 years onset\n- Adult: Motor neuron disease-like\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Hexosaminidase A (HEXA)\n- **Testing**: \n  - Enzyme activity (serum, WBC)\n  - Carrier: Enzyme + DNA\n  - Prenatal: CVS/amnio enzyme\n- **Pitfalls**: Pregnancy/OCP affect enzyme levels\n\n#### ğŸ¥— Treatment & Management\n- **No specific treatment**\n- **Supportive care**: \n  - Seizure management\n  - Feeding support\n  - Respiratory care\n- **Clinical trials**: Gene therapy ongoing\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: HEXA (15q23)\n- **Carrier frequency**:\n  - Ashkenazi Jewish: 1:30\n  - French Canadian: 1:30\n  - Cajun: 1:30\n  - Irish: 1:50\n  - General: 1:300\n\n#### ğŸ’ Board Pearls\n- Carrier screening success story (>90% reduction)\n- Pseudodeficiency alleles common\n- Sandhoff disease = Hex A + B deficiency\n- Test enzyme in pregnant/OCP users\n- 3 founder mutations in AJ (1278insTATC most common)\n\n---\n\n### Niemann-Pick Disease Types A/B â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Hepatosplenomegaly**\n2. **Cherry-red spot** (Type A)\n3. **Interstitial lung disease** (Type B)\n\n#### ğŸ¥ Clinical Features\n**Type A (Neuronopathic)**:\n- Onset <6 months\n- Massive hepatosplenomegaly\n- Neurodegeneration\n- Cherry-red spot (50%)\n- Death by 2-3 years\n\n**Type B (Non-neuronopathic)**:\n- Hepatosplenomegaly\n- Interstitial lung disease\n- Thrombocytopenia\n- Normal intelligence\n- Survival to adulthood\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Acid sphingomyelinase (SMPD1)\n- **Testing**: \n  - Enzyme activity\n  - â†‘ Sphingomyelin\n  - Gene sequencing\n- **Pathology**: Foam cells (Niemann-Pick cells)\n\n#### ğŸ¥— Treatment & Management\n- **Type B**: \n  - ERT in clinical trials\n  - Supportive care\n  - Monitor pulmonary function\n- **Type A**: Supportive only\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Carrier frequency (AJ)**: 1:80-100\n- **Common AJ mutations**: R496L, L302P, fsP330\n\n---\n\n### Niemann-Pick Disease Type C â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Vertical supranuclear gaze palsy**\n2. **Progressive neurodegeneration**\n3. **Hepatosplenomegaly** (variable)\n\n#### ğŸ¥ Clinical Features\n- **Classic (childhood)**: \n  - Ataxia\n  - Vertical gaze palsy (pathognomonic)\n  - Dysarthria, dysphagia\n  - Cognitive decline\n  - Psychiatric symptoms\n- **Variants**: Neonatal hepatitis, adult psychiatric\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: NPC1 (95%) or NPC2 (5%)\n- **Function**: Cholesterol trafficking\n- **Testing**: \n  - Filipin staining (fibroblasts)\n  - Oxysterol biomarkers\n  - Gene sequencing\n\n#### ğŸ¥— Treatment & Management\n- **Miglustat**: Substrate reduction\n- **Supportive**: Antiepileptics, psychiatry\n- **Experimental**: Cyclodextrin\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Prevalence**: 1:100,000\n- **Not part of AJ panel**\n\n---\n\n### Fabry Disease â­â­â­\n**X-linked LSD - Different from Others\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Acroparesthesias** (burning pain)\n2. **Angiokeratomas**\n3. **Corneal whorling**\n\n#### ğŸ¥ Clinical Features\n**Males (Classic)**:\n- Pain crises (hands/feet)\n- Angiokeratomas (bathing suit area)\n- Hypohidrosis\n- Corneal verticillata\n- Progressive renal failure\n- Cardiac (LVH, arrhythmias)\n- Stroke risk\n\n**Females**:\n- Variable (X-inactivation)\n- Corneal whorling common\n- Can be as severe as males\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Î±-galactosidase A (GLA)\n- **Testing**: \n  - Males: Enzyme activity\n  - Females: DNA (enzyme unreliable)\n  - â†‘ Gb3 in urine\n- **NBS**: Some states piloting\n\n#### ğŸ¥— Treatment & Management\n- **ERT**: Agalsidase beta (Fabrazyme)\n- **Oral chaperone**: Migalastat (amenable mutations)\n- **Symptomatic**: \n  - Pain management\n  - ACE inhibitors\n  - Dialysis/transplant\n- **Monitoring**: Renal, cardiac, neuro\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: X-linked\n- **Gene**: GLA (Xq22)\n- **Prevalence**: 1:40,000-60,000 males\n- **Later-onset variants**: More common\n\n#### ğŸ’ Board Pearls\n- Females are not just carriers\n- Enzyme testing unreliable in females\n- Corneal whorling doesn't affect vision\n- Later-onset cardiac variants common\n- Consider in young stroke\n\n---\n\n### Krabbe Disease â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Extreme irritability** (inconsolable crying)\n2. **Optic atrophy**\n3. **Rapid neurodegeneration**\n\n#### ğŸ¥ Clinical Features\n**Infantile (85-90%)**:\n- Normal at birth\n- Irritability by 3-6 months\n- Feeding difficulties\n- Stiffness, opisthotonus\n- Vision loss\n- Death by 2 years\n\n**Later-onset**:\n- Variable presentation\n- Gait abnormalities\n- Vision loss\n- Slower progression\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Galactocerebrosidase (GALC)\n- **Testing**: \n  - Enzyme activity\n  - â†‘ Psychosine (toxic)\n  - Gene sequencing\n- **NBS**: Few states (NY)\n\n#### ğŸ¥— Treatment & Management\n- **HSCT**: If presymptomatic or minimal symptoms\n- **Supportive care**: Most cases\n- **Timing critical**: Must treat before symptoms\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: GALC (14q31)\n- **Prevalence**: 1:100,000\n- **30kb deletion**: Common severe mutation\n\n#### ğŸ’ Board Pearls\n- No organomegaly (unlike other LSDs)\n- NBS controversial due to variants\n- HSCT only if presymptomatic\n- Psychosine is toxic metabolite\n\n---\n\n## ğŸ§¬ MUCOPOLYSACCHARIDOSES (MPS)\n\n### MPS I (Hurler/Scheie Syndrome) â­â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Coarse facial features**\n2. **Corneal clouding**\n3. **Dysostosis multiplex**\n\n#### ğŸ¥ Clinical Features\n**Hurler (Severe)**:\n- Onset <2 years\n- Profound ID\n- Coarse features by 1 year\n- Corneal clouding\n- Organomegaly\n- Cardiac disease\n- Death by 10 without treatment\n\n**Scheie (Mild)**:\n- Normal intelligence\n- Joint stiffness\n- Corneal clouding\n- Cardiac valves\n- Normal lifespan\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Î±-L-iduronidase\n- **GAGs**: â†‘ Dermatan sulfate, â†‘ Heparan sulfate\n- **Testing**: \n  - Enzyme activity\n  - Urine GAGs (screening)\n  - Molecular confirmation\n- **X-rays**: Dysostosis multiplex\n\n#### ğŸ¥— Treatment & Management\n- **ERT**: Laronidase (Aldurazyme)\n  - Doesn't cross BBB\n  - Improves somatic features\n- **HSCT**: For Hurler syndrome\n  - Best <2 years\n  - Can preserve cognition\n- **Supportive**: ENT, ortho, cardio\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: IDUA (4p16.3)\n- **Prevalence**: 1:100,000\n- **Common mutations**: W402X, Q70X\n\n#### ğŸ’ Board Pearls\n- Hurler-Scheie = intermediate phenotype\n- HSCT + ERT may be combined\n- Corneal clouding in all forms\n- Most common MPS\n\n---\n\n### MPS II (Hunter Syndrome) â­â­â­\n**Only X-linked MPS\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **NO corneal clouding** (vs MPS I)\n2. **Pebbly skin lesions**\n3. **X-linked inheritance**\n\n#### ğŸ¥ Clinical Features\n**Severe form**:\n- Similar to Hurler but X-linked\n- Progressive ID\n- Behavioral issues\n- No corneal clouding\n- Characteristic skin lesions\n\n**Attenuated form**:\n- Normal/mild ID\n- Joint stiffness\n- Cardiac involvement\n- Survival to adulthood\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Iduronate-2-sulfatase (I2S)\n- **GAGs**: â†‘ Dermatan sulfate, â†‘ Heparan sulfate\n- **Testing**: \n  - Enzyme activity\n  - Molecular (deletions common)\n\n#### ğŸ¥— Treatment & Management\n- **ERT**: Idursulfase (Elaprase)\n- **No HSCT benefit** (unlike MPS I)\n- **Supportive care**\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: X-linked recessive\n- **Gene**: IDS (Xq28)\n- **Prevalence**: 1:100,000-170,000 males\n- **Carrier testing**: Important for families\n\n#### ğŸ’ Board Pearls\n- NO corneal clouding (key difference from MPS I)\n- Pebbly skin lesions (pathognomonic)\n- Behavioral issues common\n- Female carriers usually asymptomatic\n\n---\n\n### MPS III (Sanfilippo Syndrome) â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Severe behavioral problems**\n2. **Relatively mild somatic features**\n3. **Progressive ID**\n\n#### ğŸ¥ Clinical Features\n- **Topics**:\n  1. Developmental delay (1-3 years)\n  2. Behavioral issues (3-10 years)\n     - Hyperactivity\n     - Sleep disturbance\n     - Aggression\n  3. Neurodegeneration (>10 years)\n- **Mild coarse features**\n- **Normal height**\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: Four different enzymes (A, B, C, D)\n- **GAG**: â†‘ Heparan sulfate only\n- **Testing**: Specific enzyme based on subtype\n\n#### ğŸ¥— Treatment & Management\n- **No approved treatment**\n- **Behavioral management**\n- **Clinical trials**: Gene therapy\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Prevalence**: 1:70,000 (all types)\n- **Type A most common**\n\n#### ğŸ’ Board Pearls\n- Most severe CNS involvement of MPS\n- Behavior > physical features\n- Four different subtypes (A-D)\n- No dermatan sulfate (unlike I, II)\n\n---\n\n## ğŸ§¬ PEROXISOMAL & FATTY ACID OXIDATION DISORDERS\n\n### X-linked Adrenoleukodystrophy (X-ALD) â­â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Adrenal insufficiency**\n2. **Progressive white matter disease**\n3. **Very long chain fatty acids (VLCFA)**\n\n#### ğŸ¥ Clinical Phenotypes\n**Childhood cerebral (35%)**:\n- Normal until 4-10 years\n- Behavioral changes\n- Rapid neurodegeneration\n- Adrenal insufficiency\n- Death within 2-4 years\n\n**Adrenomyeloneuropathy (AMN)**:\n- Adult onset (20-30s)\n- Progressive paraparesis\n- Peripheral neuropathy\n- Adrenal insufficiency (70%)\n\n**Addison disease only (10%)**:\n- Isolated adrenal insufficiency\n- Can progress to other forms\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: ABCD1 (peroxisomal transporter)\n- **Testing**: \n  - â†‘ VLCFA (C26:0, C24:0)\n  - ACTH stimulation test\n  - Brain MRI\n  - Gene sequencing\n- **NBS**: Some states\n\n#### ğŸ¥— Treatment & Management\n- **Adrenal**: Hormone replacement\n- **Cerebral ALD**: \n  - HSCT if early (Loes score <9)\n  - Lorenzo's oil (questionable benefit)\n- **Monitoring**: \n  - Annual MRI (boys 3-12)\n  - Adrenal function\n- **Gene therapy**: Clinical trials\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: X-linked\n- **Gene**: ABCD1 (Xq28)\n- **Prevalence**: 1:20,000-50,000\n- **Penetrance**: Variable, even within families\n\n#### ğŸ’ Board Pearls\n- Female carriers can be symptomatic (AMN-like)\n- No genotype-phenotype correlation\n- Screen all males with Addison's\n- HSCT only helps if early cerebral\n- Different from neonatal ALD (Zellweger)\n\n---\n\n### Zellweger Syndrome â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Severe hypotonia** (neonatal)\n2. **Characteristic facies** (high forehead)\n3. **Hepatomegaly**\n\n#### ğŸ¥ Clinical Features\n- **Craniofacial**: High forehead, large fontanelles\n- **Neurologic**: Profound hypotonia, seizures\n- **Hepatic**: Hepatomegaly, jaundice\n- **Skeletal**: Stippled epiphyses\n- **Ocular**: Cataracts, glaucoma\n- **Death**: Usually <1 year\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: PEX genes (peroxisome biogenesis)\n- **Testing**: \n  - â†‘ VLCFA\n  - â†‘ Pipecolic acid\n  - Abnormal bile acids\n  - Plasmalogen deficiency\n\n#### ğŸ¥— Treatment & Management\n- **Supportive care only**\n- **No specific treatment**\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Genes**: PEX1 most common (70%)\n- **Prevalence**: 1:50,000\n\n#### ğŸ’ Board Pearls\n- Most severe peroxisomal disorder\n- Spectrum includes NALD, IRD\n- Stippled epiphyses on X-ray\n- Multiple peroxisomal functions affected\n\n---\n\n### Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD) â­â­â­\n**Most Common FAO Disorder\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Hypoketotic hypoglycemia**\n2. **Hepatomegaly** during crisis\n3. **\"SIDS-like\" presentation**\n\n#### ğŸ¥ Clinical Features\n- **Typical presentation**: \n  - Well until metabolic stress\n  - Vomiting, lethargy\n  - Hypoglycemia\n  - Can progress to coma/death\n- **Triggers**: Fasting, illness\n- **Age**: Usually 3-24 months\n- **Between episodes**: Normal\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: ACADM gene\n- **NBS**: â†‘ C8 (octanoylcarnitine)\n- **Confirmation**: \n  - Acylcarnitine profile\n  - Urine organic acids (crisis)\n  - Gene sequencing\n- **Common mutation**: c.985A>G (K329E)\n\n#### ğŸ¥— Treatment & Management\n- **Avoid fasting**: \n  - <6 months: q3-4h\n  - 6-12 months: q4-6h\n  - >1 year: max 8-10h\n- **Emergency protocol**: \n  - IV dextrose for illness\n  - Written plan for families\n- **Diet**: Normal fat content OK\n- **Carnitine**: If deficient\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: ACADM (1p31)\n- **Prevalence**: 1:15,000\n- **Carrier frequency**: 1:60 (Northern European)\n- **NBS success**: Prevents most deaths\n\n#### ğŸ’ Board Pearls\n- #1 cause of \"near-miss SIDS\"\n- K329E mutation in 80% of alleles\n- Normal between episodes\n- Excellent prognosis if fasting avoided\n- Some never have symptoms (NBS finding)\n\n---\n\n## ğŸ§¬ METAL TRANSPORT DISORDERS\n\n### Wilson Disease â­â­â­\n**Treatable Cause of Liver Disease + Neuropsychiatric\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Kayser-Fleischer rings**\n2. **Liver disease** (varies)\n3. **Neuropsychiatric symptoms**\n\n#### ğŸ¥ Clinical Features\n**Hepatic (40%)**:\n- Acute hepatitis\n- Chronic hepatitis\n- Cirrhosis\n- Fulminant hepatic failure\n\n**Neurologic (40%)**:\n- Tremor (wing-beating)\n- Dystonia\n- Dysarthria\n- Dysphagia\n- Parkinsonism\n\n**Psychiatric (20%)**:\n- Personality changes\n- Depression\n- Psychosis\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: ATP7B (copper transport)\n- **Testing**: \n  - â†“ Ceruloplasmin (<20)\n  - â†‘ 24hr urine copper (>100)\n  - â†‘ Hepatic copper\n  - K-F rings (slit lamp)\n- **Gene sequencing**: >500 mutations\n\n#### ğŸ¥— Treatment & Management\n- **Chelation**: \n  - Penicillamine\n  - Trientine\n  - Zinc (blocks absorption)\n- **Diet**: Avoid high copper foods\n- **Monitoring**: 24hr urine copper\n- **Liver transplant**: If fulminant failure\n- **Family screening**: Essential\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: ATP7B (13q14)\n- **Prevalence**: 1:30,000\n- **Age of onset**: 6-45 years\n- **High risk**: Sardinia, Japan\n\n#### ğŸ’ Board Pearls\n- K-F rings absent in 50% with liver disease\n- Low alkaline phosphatase in fulminant failure\n- Screen siblings (even if asymptomatic)\n- Pregnancy: Continue treatment\n- Treatable â†’ great prognosis if caught early\n\n---\n\n### Menkes Disease â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Kinky/steely hair**\n2. **Severe neurodegeneration**\n3. **Connective tissue abnormalities**\n\n#### ğŸ¥ Clinical Features\n- **Hair**: Sparse, brittle, twisted (pili torti)\n- **Neurologic**: Hypotonia, seizures, ID\n- **Vascular**: Tortuous vessels, aneurysms\n- **Skeletal**: Osteoporosis, fractures\n- **Skin**: Lax, doughy\n- **Temperature instability**\n- **Death**: Usually by 3 years\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: ATP7A (copper transport)\n- **Testing**: \n  - â†“ Serum copper\n  - â†“ Ceruloplasmin\n  - Gene sequencing\n- **Prenatal**: Copper in CVS\n\n#### ğŸ¥— Treatment & Management\n- **Copper histidine**: Subcutaneous\n  - Must start <2 months\n  - Limited benefit if started late\n- **Supportive care**\n- **Genetic counseling**: X-linked\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: X-linked recessive\n- **Gene**: ATP7A (Xq21.1)\n- **Prevalence**: 1:100,000-250,000\n- **Allelic**: Occipital horn syndrome (milder)\n\n#### ğŸ’ Board Pearls\n- Opposite of Wilson (copper deficiency)\n- Hair abnormalities pathognomonic\n- Female carriers: 50% have pili torti\n- Early treatment critical but limited benefit\n\n---\n\n## ğŸ§¬ OTHER KEY METABOLIC DISORDERS\n\n### Smith-Lemli-Opitz Syndrome â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **2-3 toe syndactyly** (Y-shaped)\n2. **Microcephaly**\n3. **Hypospadias/genital abnormalities**\n\n#### ğŸ¥ Clinical Features\n- **Growth**: IUGR, FTT, short stature\n- **Craniofacial**: Microcephaly, ptosis, anteverted nares\n- **Limbs**: 2-3 toe syndactyly (characteristic)\n- **Genitourinary**: Hypospadias, cryptorchidism, sex reversal\n- **Cardiac**: ASD, VSD common\n- **GI**: Pyloric stenosis, Hirschsprung\n- **Behavioral**: Autism-like, self-injury\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: DHCR7 (cholesterol synthesis)\n- **Testing**: \n  - â†‘ 7-dehydrocholesterol\n  - â†“ Cholesterol\n  - Gene sequencing\n- **Prenatal**: Low uE3 (not specific)\n\n#### ğŸ¥— Treatment & Management\n- **Cholesterol supplementation**\n  - Variable response\n  - May improve growth\n- **Behavioral interventions**\n- **Surgical**: For malformations\n- **Monitoring**: Growth, development\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal recessive\n- **Gene**: DHCR7 (11q13.4)\n- **Prevalence**: 1:20,000-60,000\n- **Carrier frequency**: 1:30 (Europeans)\n\n#### ğŸ’ Board Pearls\n- 2-3 toe syndactyly = pathognomonic\n- Can have 46,XY sex reversal\n- Cholesterol precursor is toxic\n- Variable severity\n- Consider in autism + dysmorphism\n\n---\n\n### Lesch-Nyhan Syndrome â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Self-mutilation** (lip/finger biting)\n2. **Dystonia/choreoathetosis**\n3. **Hyperuricemia**\n\n#### ğŸ¥ Clinical Features\n- **Neurologic**: \n  - Hypotonia â†’ dystonia\n  - Choreoathetosis\n  - Spasticity\n  - ID (mild-moderate)\n- **Behavioral**: \n  - Compulsive self-injury\n  - Aggression\n  - Anxiety\n- **Metabolic**: \n  - Hyperuricemia\n  - Orange crystals in diapers\n  - Nephrolithiasis\n  - Gout (if untreated)\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: HPRT1 (purine salvage)\n- **Testing**: \n  - â†‘ Uric acid\n  - HPRT enzyme activity\n  - Gene sequencing\n- **Carrier testing**: Enzyme assay unreliable\n\n#### ğŸ¥— Treatment & Management\n- **Allopurinol**: Prevents gout/stones\n  - Doesn't help neurologic\n- **Protective devices**: Prevent self-injury\n- **Behavioral management**\n- **Physical therapy**\n- **Dental extraction**: Sometimes necessary\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: X-linked recessive\n- **Gene**: HPRT1 (Xq26)\n- **Prevalence**: 1:380,000\n- **Variants**: Partial deficiency = gout only\n\n#### ğŸ’ Board Pearls\n- Self-mutilation is compulsive, not voluntary\n- Orange crystals in diapers = first sign\n- Allopurinol doesn't help neuro symptoms\n- Female carriers rarely symptomatic\n- HPRT <1.5% = Lesch-Nyhan\n\n---\n\n### Familial Hypercholesterolemia â­â­â­\n**Most Common AD Metabolic Disorder\\!**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Very high LDL** (>190 adults, >160 children)\n2. **Tendon xanthomas**\n3. **Premature CAD**\n\n#### ğŸ¥ Clinical Features\n**Heterozygotes**:\n- LDL 2-3x normal\n- Xanthomas (30-50%)\n- Corneal arcus <45y\n- CAD: Men 40-50s, Women 50-60s\n\n**Homozygotes**:\n- LDL >500\n- Xanthomas in childhood\n- Aortic stenosis\n- CAD in teens/20s\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defects**: \n  - LDLR (85%)\n  - APOB (5%)\n  - PCSK9 (gain of function)\n- **Testing**: \n  - Lipid panel\n  - Genetic testing\n  - Cascade screening\n- **Dutch Lipid Clinic criteria**\n\n#### ğŸ¥— Treatment & Management\n**Children**:\n- Start statins by 8-10y\n- LDL goal <130\n\n**Adults**:\n- High-intensity statins\n- Ezetimibe\n- PCSK9 inhibitors\n- LDL goal <70 (or 50% reduction)\n\n**Homozygotes**:\n- LDL apheresis\n- Lomitapide, evinacumab\n- Liver transplant\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal dominant\n- **Prevalence**: \n  - Heterozygotes: 1:250\n  - Homozygotes: 1:160,000-300,000\n- **Founder effects**: \n  - French Canadians: 1:270\n  - Afrikaners: 1:70\n  - Lebanese: 1:170\n\n#### ğŸ’ Board Pearls\n- Most common AD metabolic disorder\n- Untreated heterozygotes: 50% CAD by 50 (men)\n- Cascade screening cost-effective\n- Statins safe in pregnancy controversy\n- Consider if LDL >190 (adults) or >160 (kids)\n\n---\n\n### Mitochondrial Disorders â­â­\n\n#### Overview\n- **Dual genome**: mtDNA + nuclear DNA\n- **Maternal inheritance**: mtDNA mutations\n- **Heteroplasmy**: Variable mutation load\n- **Multi-system**: High energy organs affected\n\n### MELAS â­â­\n**Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like episodes**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Stroke-like episodes** (not vascular)\n2. **Lactic acidosis**\n3. **Ragged red fibers**\n\n#### ğŸ¥ Clinical Features\n- Onset: 2-40 years\n- Stroke-like episodes\n- Seizures\n- Migraines\n- Short stature\n- Diabetes\n- Hearing loss\n\n#### ğŸ§ª Testing\n- â†‘ Lactate (blood, CSF)\n- MRI: Cortical lesions (not vascular)\n- Muscle biopsy: RRF\n- mtDNA: m.3243A>G (80%)\n\n#### ğŸ“ˆ Inheritance\n- Maternal (mitochondrial)\n- Variable expression\n- Genetic counseling complex\n\n---\n\n### MERRF â­\n**Myoclonic Epilepsy with Ragged Red Fibers**\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Myoclonic seizures**\n2. **Ataxia**\n3. **Ragged red fibers**\n\n#### ğŸ¥ Clinical Features\n- Myoclonus\n- Generalized seizures\n- Cerebellar ataxia\n- Muscle weakness\n- Dementia\n\n#### ğŸ§ª Testing\n- EEG: Generalized spike-wave\n- Muscle biopsy: RRF\n- mtDNA: m.8344A>G (80%)\n\n---\n\n### Acute Intermittent Porphyria â­â­\n\n#### ğŸ”‘ Key Features (Top 3)\n1. **Acute abdominal pain**\n2. **Neuropsychiatric symptoms**\n3. **Port wine urine**\n\n#### ğŸ¥ Clinical Features\n- **Acute attacks**: \n  - Severe abdominal pain\n  - Vomiting\n  - Constipation\n  - Tachycardia, HTN\n- **Neurologic**: \n  - Peripheral neuropathy\n  - Seizures\n  - Psychosis\n- **Triggers**: \n  - Drugs (barbiturates)\n  - Hormones\n  - Fasting\n  - Stress\n\n#### ğŸ§ª Biochemistry & Testing\n- **Defect**: HMBS (porphobilinogen deaminase)\n- **Testing (acute)**: \n  - â†‘ Urine PBG, ALA\n  - Port wine urine\n- **Testing (between)**: \n  - May be normal\n  - Gene sequencing\n\n#### ğŸ¥— Treatment & Management\n- **Acute**: \n  - IV hemin\n  - Glucose\n  - Pain control\n- **Prevention**: \n  - Avoid triggers\n  - Drug list\n- **New**: Givosiran (siRNA)\n\n#### ğŸ“ˆ Inheritance & Statistics\n- **Pattern**: Autosomal dominant\n- **Penetrance**: ~10-20%\n- **Prevalence**: 1:20,000\n- **Higher in**: Sweden, Finland\n\n#### ğŸ’ Board Pearls\n- 90% never have symptoms\n- Attacks rare before puberty\n- Safe drugs: Morphine OK\n- Urine normal between attacks\n- Consider in unexplained abdominal pain\n\n---\n\n## ğŸ“‹ Study Aids & Mnemonics\n\n### NBS Conditions by Category\n\n**Amino Acid Disorders**:\n- PKU\n- MSUD\n- Homocystinuria (some states)\n- Tyrosinemia\n\n**Organic Acidemias**:\n- MMA\n- PA\n- IVA\n- GA-1\n\n**Fatty Acid Oxidation**:\n- MCAD\n- VLCAD\n- LCHAD\n\n**Others**:\n- Galactosemia\n- Biotinidase deficiency\n- CAH\n\n### Population Carrier Screening\n\n**Ashkenazi Jewish Panel**:\n1. Tay-Sachs (1:30)\n2. Gaucher (1:15)\n3. Canavan (1:40)\n4. Familial dysautonomia (1:30)\n5. Niemann-Pick A (1:90)\n6. Bloom syndrome (1:100)\n7. Fanconi anemia C (1:90)\n8. Mucolipidosis IV (1:125)\n\n### Metabolic Emergency Protocol\n**\"STOP\"**:\n- **S**top protein\n- **T**reat with IV dextrose\n- **O**btain labs\n- **P**revent catabolism\n\n### Enzyme Replacement Available\n**\"GIFT FANG\"**:\n- **G**aucher\n- **I**migen (Pompe)\n- **F**abry\n- **T**ay-Sachs (trials)\n- **F**ucosidosis (trials)\n- **A**LD (trials)\n- **N**iemann-Pick B (trials)\n- **G**lycogen storage disease II\n\n### Diet Restrictions\n**\"PKU GAL MSUD\"**:\n- **P**KU: Low phenylalanine\n- **K**eep monitoring\n- **U**rgent if pregnant\n- **G**alactosemia: No galactose\n- **A**void dairy\n- **L**ifelong\n- **M**SUD: Low BCAA\n- **S**mell maple syrup\n- **U**rgent dialysis\n- **D**ietary compliance\n\n---\n\n## ğŸ¯ High-Yield Board Facts\n\n### Newborn Screening\n1. **PKU**: Most common amino acid disorder on NBS\n2. **MCAD**: Most common FAO disorder\n3. **False positives**: Common with prematurity, TPN\n4. **False negatives**: Can occur if tested too early\n5. **Transfusion**: Affects galactosemia, biotinidase\n\n### Carrier Frequencies\n1. **Highest in AJ**: Gaucher (1:15)\n2. **Pan-ethnic high**: PKU (1:50), FH (1:250)\n3. **Founder effects**: French Canadian (multiple)\n\n### Treatment Pearls\n1. **Diet from birth**: PKU, galactosemia, MSUD\n2. **ERT available**: Gaucher, Fabry, Pompe, MPS I/II\n3. **Vitamin responsive**: B6 (homocystinuria), B12 (MMA)\n4. **Liver transplant curative**: Tyrosinemia, some UCDs\n\n### Inheritance Patterns\n1. **AR**: Most metabolic disorders\n2. **XLR**: Fabry, Hunter, ALD, Menkes, Lesch-Nyhan\n3. **AD**: FH, acute porphyrias\n4. **Maternal**: Mitochondrial disorders\n\n### Emergency Management\n1. **NPO + D10**: First step for most\n2. **Dialysis**: MSUD, hyperammonemia\n3. **Written protocol**: Essential for families\n4. **Avoid catabolism**: Key principle\n\n---\n\n## ğŸ“ Practice Questions\n\n### Question 1\nA 6-month-old presents with poor feeding, vomiting, and lethargy after a viral illness. Labs show hypoglycemia without ketones, elevated liver enzymes, and hyperammonemia. Acylcarnitine profile shows elevated C8. What is the most likely diagnosis?\n\nA) MCAD deficiency\nB) Propionic acidemia  \nC) Glycogen storage disease I\nD) Ornithine transcarbamylase deficiency\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A - MCAD deficiency**\n- Hypoketotic hypoglycemia is classic\n- C8 elevation specific for MCAD\n- Triggered by illness/fasting\n- Hyperammonemia can occur\n</details>\n\n### Question 2\nA couple of Ashkenazi Jewish descent requests carrier screening. The woman is found to be a carrier for Gaucher disease. What is the chance their child will be affected if the man is also of 100% Ashkenazi Jewish descent?\n\nA) 1:60\nB) 1:120  \nC) 1:240\nD) 1:900\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A - 1:60**\n- Woman is carrier (confirmed)\n- Man's carrier risk: 1:15 (AJ population)\n- Risk calculation: 1 Ã— 1/15 Ã— 1/4 = 1/60\n</details>\n\n### Question 3\nA 2-year-old boy presents with coarse facial features, developmental delay, and chronic ear infections. Physical exam reveals hepatosplenomegaly and limited joint mobility. Urine GAGs show increased heparan and dermatan sulfate. His maternal uncle died at age 8 with similar features. What is the most likely diagnosis?\n\nA) MPS I (Hurler syndrome)\nB) MPS II (Hunter syndrome)\nC) MPS III (Sanfilippo syndrome)  \nD) Gaucher disease\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B - MPS II (Hunter syndrome)**\n- X-linked inheritance (affected uncle, mother carrier)\n- Heparan + dermatan sulfate\n- Coarse features + organomegaly\n- MPS I is AR, not X-linked\n</details>\n\n### Question 4\nA newborn screens positive for elevated phenylalanine. Confirmatory testing shows Phe 1450 Î¼mol/L (normal <120). The parents ask about recurrence risk. What counseling is most appropriate?\n\nA) 25% for all pregnancies\nB) 50% for males only\nC) <1% above general population risk\nD) Depends on maternal diet during pregnancy\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: A - 25% for all pregnancies**\n- PKU is autosomal recessive\n- Both parents must be carriers\n- Standard AR recurrence risk\n- Maternal diet affects teratogenicity, not recurrence\n</details>\n\n### Question 5\nA 35-year-old woman with PKU (diagnosed by NBS, poorly controlled) presents at 8 weeks gestation. Her Phe level is 850 Î¼mol/L. What is her fetus at highest risk for?\n\nA) PKU\nB) Microcephaly\nC) Galactosemia\nD) Neural tube defects\n\n<details>\n<summary>Click for answer</summary>\n\n**Answer: B - Microcephaly**\n- Maternal PKU syndrome\n- High Phe is teratogenic\n- Microcephaly most common (73%)\n- Fetus is obligate carrier, not affected\n</details>\n\n---\n\n## âœ… Topic 5 Completion Checklist\n\n### âœ… Core Knowledge Areas\n- [ ] Know which disorders are included in newborn screening\n- [ ] Understand PKU classification and maternal PKU syndrome\n- [ ] Master Ashkenazi Jewish carrier screening panel\n- [ ] Recognize emergency presentations (MCAD, MSUD, MMA)\n- [ ] Distinguish lysosomal storage disorders by features\n- [ ] Know inheritance patterns (AR vs X-linked disorders)\n- [ ] Understand enzyme replacement therapy options\n- [ ] Recognize Gaucher disease genotype-phenotype correlations\n- [ ] Know Wilson vs Menkes disease differences\n- [ ] Master familial hypercholesterolemia management\n\n### ğŸ¯ Clinical Skills\n- [ ] Can calculate carrier screening risks\n- [ ] Understand dietary management principles\n- [ ] Know emergency protocols for metabolic crises\n- [ ] Recognize when to suspect metabolic disorders\n- [ ] Can counsel about treatment compliance challenges\n- [ ] Apply population-specific screening recommendations\n\n### ğŸ“š Test Preparation\n- [ ] Completed all practice questions successfully\n- [ ] Reviewed mnemonics and memory aids\n- [ ] Know high-yield statistics and carrier frequencies\n- [ ] Understand biochemical pathways and testing\n- [ ] Memorized treatment approaches and outcomes\n- [ ] Created flashcards for enzyme deficiencies\n\n### ğŸ”„ Final Review\n- [ ] Cross-referenced with newborn screening protocols\n- [ ] Verified population carrier frequencies\n- [ ] Confirmed treatment guidelines and monitoring\n- [ ] Reviewed emergency management protocols\n\n---\n\n## ğŸ“ Key Takeaway Messages\n\n1. **Newborn screening** prevents most severe outcomes for treatable conditions\n2. **Population screening** is most effective for high-risk groups (AJ, Cajun, etc.)\n3. **Dietary compliance** is lifelong and challenging, especially in adolescence\n4. **Emergency protocols** are critical for organic acidemias and FAO disorders\n5. **Enzyme replacement** available for several LSDs but costly and complex\n6. **X-linked disorders** have different inheritance patterns (Fabry, Hunter, etc.)\n7. **Carrier testing** essential for affected families and high-risk populations\n8. **Metabolic crises** require immediate intervention to prevent permanent damage\n9. **Genotype-phenotype** correlations guide prognosis and treatment\n10. **Multidisciplinary care** essential for optimal outcomes\n\n---\n\n## ğŸ”— Navigation\n\n**[â¬†ï¸ Back to Master Index](study-guide-master-index.md)** | **[â¬…ï¸ Previous: Neurological Disorders](topic4-neurological-developmental.md)** | **[â¡ï¸ Next Topic: Final Topic](topic6-final-topic.md)**\n\n---\n\n**ğŸ•’ Study Time Recommendation:** 15-18 hours  \n**ğŸ—“ï¸ Review Schedule:** Review this topic after completing Topic 6\n\n**ğŸ† Completion Status:** Topic 5 of 6 complete\n\n---\n\n**Remember:** This guide covers testable material for the genetic counseling board exam. Focus on recognition patterns, inheritance risks, and treatment strategies rather than detailed molecular mechanisms.\n\nGood luck with your studies\\! ğŸ§¬"
}